BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Friis-Møller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003. [PMID: 14627784 DOI: 10.1056/nejmoa030218] [Cited by in Crossref: 1138] [Cited by in F6Publishing: 425] [Article Influence: 59.9] [Reference Citation Analysis]
Number Citing Articles
1 Meng Z, Hernandez R, Liu J, Gwag T, Lu W, Hsiai TK, Kaul M, Zhou T, Zhou C. HIV Protein Tat Induces Macrophage Dysfunction and Atherosclerosis Development in Low-Density Lipoprotein Receptor-Deficient Mice. Cardiovasc Drugs Ther 2021. [PMID: 33459922 DOI: 10.1007/s10557-021-07141-x] [Reference Citation Analysis]
2 Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, Trottier B, Routy JP, Cote P, Abribat T, Grinspoon S. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005;19:1279-87. [PMID: 16052083 DOI: 10.1097/01.aids.0000180099.35146.30] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
3 Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667-78. [PMID: 20523203 DOI: 10.1097/QAD.0b013e328339fe53] [Cited by in Crossref: 300] [Cited by in F6Publishing: 159] [Article Influence: 25.0] [Reference Citation Analysis]
4 Masiá M, Padilla S, Álvarez D, López JC, Santos I, Soriano V, Hernández-Quero J, Santos J, Tural C, del Amo J, Gutiérrez F; CoRIS. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy. AIDS 2013;27:181-9. [PMID: 23018442 DOI: 10.1097/QAD.0b013e32835a1156] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 5.1] [Reference Citation Analysis]
5 Monroe AK, Dobs AS, Xu X, Palella FJ, Kingsley LA, Post WS, Witt MD, Brown TT. Low free testosterone in HIV-infected men is not associated with subclinical cardiovascular disease. HIV Med 2012;13:358-66. [PMID: 22296297 DOI: 10.1111/j.1468-1293.2011.00988.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
6 Zaaqoq AM, Khasawneh FA, Smalligan RD. Cardiovascular Complications of HIV-Associated Immune Dysfunction. Cardiol Res Pract 2015;2015:302638. [PMID: 25648075 DOI: 10.1155/2015/302638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
7 Poizot-Martin I, Marimoutou C, Drogoul-Vey MP, Vion-Dury F, Frixon-Marin V, Benhaim S, Poggi P, Gastaut JA. Nelfinavir in HIV-HCV coinfected patients: a 24-month follow-up in a cohort of 82 patients. AIDS Res Hum Retroviruses 2005;21:841-4. [PMID: 16225410 DOI: 10.1089/aid.2005.21.841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Carosi G, Nasta P, Fiore S, Matteelli A, Cauda R, Ferrazzi E, Tamburrini E, Savasi V, Bini T, Ravizza M, Bucceri A, Vichi F, Murri R, Mazzotta F, d'Arminio Monforte A; Italian Working Group for the Women with HIV Management Guidelines. Women facing HIV. Key question on women with HIV infection: Italian consensus workshop. Infection 2009;37:168-78. [PMID: 19308320 DOI: 10.1007/s15010-008-7361-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Lai S, Bartlett J, Lai H, Moore R, Cofrancesco J Jr, Pannu H, Tong W, Meng W, Sun H, Fishman EK. Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection. AIDS Patient Care STDS 2009;23:815-24. [PMID: 19803679 DOI: 10.1089/apc.2009.0048] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
10 Tsai A, Irrinki A, Kaur J, Cihlar T, Kukolj G, Sloan DD, Murry JP. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. J Virol 2017;91:e02166-16. [PMID: 28179531 DOI: 10.1128/JVI.02166-16] [Cited by in Crossref: 77] [Cited by in F6Publishing: 53] [Article Influence: 15.4] [Reference Citation Analysis]
11 Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Curr HIV/AIDS Rep 2005;2:132-9. [PMID: 16091260 DOI: 10.1007/s11904-005-0006-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
12 Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab 2008;93:2937-45. [PMID: 18685115 DOI: 10.1210/jc.2008-1019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
13 Dickens AM, Yoo SW, Chin AC, Xu J, Johnson TP, Trout AL, Hauser KF, Haughey NJ. Chronic low-level expression of HIV-1 Tat promotes a neurodegenerative phenotype with aging. Sci Rep 2017;7:7748. [PMID: 28798382 DOI: 10.1038/s41598-017-07570-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
14 Leyes P, Cofan M, González-Cordón A, de Lazzari E, Trabal J, Domingo P, Negredo E, Vidal F, Forga MT, Gatell JM, Ros E, Martínez E. Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. AIDS 2018;32:1309-16. [PMID: 29683854 DOI: 10.1097/QAD.0000000000001837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
15 Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, Hoh R, Martin JN, McCune JM, Waters DD, Deeks SG. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006;20:2275-83. [PMID: 17117013 DOI: 10.1097/QAD.0b013e3280108704] [Cited by in Crossref: 213] [Cited by in F6Publishing: 134] [Article Influence: 13.3] [Reference Citation Analysis]
16 Chew D, Steinberg MB, Thomas P, Swaminathan S, Hodder SL. Evaluation of a Smoking Cessation Program for HIV Infected Individuals in an Urban HIV Clinic: Challenges and Lessons Learned. AIDS Res Treat 2014;2014:237834. [PMID: 25349726 DOI: 10.1155/2014/237834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
17 Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JA. Immune activation and collateral damage in AIDS pathogenesis. Front Immunol 2013;4:298. [PMID: 24133492 DOI: 10.3389/fimmu.2013.00298] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
18 Townsend K, Meissner EG, Sidharthan S, Sampson M, Remaley AT, Tang L, Kohli A, Osinusi A, Masur H, Kottilil S. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses 2016;32:456-62. [PMID: 26559180 DOI: 10.1089/AID.2015.0170] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
19 Aboud M, Elgalib A, Pomeroy L, Panayiotakopoulos G, Skopelitis E, Kulasegaram R, Dimian C, C Lampe F, Duncan A, Wierzbicki AS, Peters BS. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract 2010;64:1252-9. [PMID: 20653801 DOI: 10.1111/j.1742-1241.2010.02424.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
20 Monforte Ad, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013;27:407-15. [PMID: 23291539 DOI: 10.1097/QAD.0b013e32835b2ef1] [Cited by in Crossref: 81] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
21 Gwag T, Meng Z, Sui Y, Helsley RN, Park SH, Wang S, Greenberg RN, Zhou C. Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis. J Hepatol 2019;70:930-40. [PMID: 30677459 DOI: 10.1016/j.jhep.2018.12.038] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
22 Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176:1113-1120. [PMID: 17420495 DOI: 10.1503/cmaj.060963] [Cited by in Crossref: 312] [Cited by in F6Publishing: 244] [Article Influence: 20.8] [Reference Citation Analysis]
23 Tebas P, Henry WK, Matining R, Weng-Cherng D, Schmitz J, Valdez H, Jahed N, Myers L, Powderly WG, Katzenstein D. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One. 2008;3:e2021. [PMID: 18431498 DOI: 10.1371/journal.pone.0002021] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
24 Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, Young M, Justman JE. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007;21:1739-45. [PMID: 17690572 DOI: 10.1097/QAD.0b013e32827038d0] [Cited by in Crossref: 136] [Cited by in F6Publishing: 72] [Article Influence: 9.1] [Reference Citation Analysis]
25 Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. AIDS 2019;33:773-91. [PMID: 30883388 DOI: 10.1097/QAD.0000000000002113] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
26 Muthukumar T, Afaneh C, Ding R, Tsapepas D, Lubetzky M, Jacobs S, Lee J, Sharma V, Lee J, Dadhania D, Hartono C, McDermott J, Aull M, Leeser D, Kapur S, Serur D, Suthanthiran M. HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. Transplantation 2013;95:711-20. [PMID: 23503504 DOI: 10.1097/TP.0b013e31827ac322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
27 Moyle G, Gatell J, Perno CF, Ratanasuwan W, Schechter M, Tsoukas C. Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. AIDS Patient Care STDS 2008;22:459-71. [PMID: 18479200 DOI: 10.1089/apc.2007.0136] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
28 Luna LD, Soares Dde S, Junior GB, Cavalcante MG, Malveira LR, Meneses GC, Pereira ED, Daher Ede F. CLINICAL CHARACTERISTICS, OUTCOMES AND RISK FACTORS FOR DEATH AMONG CRITICALLY ILL PATIENTS WITH HIV-RELATED ACUTE KIDNEY INJURY. Rev Inst Med Trop Sao Paulo 2016;58:52. [PMID: 27410912 DOI: 10.1590/S1678-9946201658052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
29 Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kamya MR. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. J Int AIDS Soc 2012;15:17427. [PMID: 22814353 DOI: 10.7448/IAS.15.2.17427] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
30 Mestres C, Miro JM. Cardiac surgery in human immunodeficiency virus positive patients. Indian J Thorac Cardiovasc Surg 2006;22:203-4. [DOI: 10.1007/s12055-006-0002-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Tien PC, Schneider MF, Cox C, Cohen M, Karim R, Lazar J, Young M, Glesby MJ. HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study. AIDS 2010;24:2809-17. [PMID: 20871387 DOI: 10.1097/QAD.0b013e32833fcb3b] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
32 Ashare RL, Wileyto EP, Logue-Chamberlain E, Gross R, Tyndale RF, Lerman C, Hawk LW, Cinciripini P, George TP, Lubitz SF, Schnoll R. Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV. Psychol Addict Behav 2020. [PMID: 32686950 DOI: 10.1037/adb0000619] [Reference Citation Analysis]
33 Ross AC, Armentrout R, O'Riordan MA, Storer N, Rizk N, Harrill D, El Bejjani D, McComsey GA. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008;49:499-506. [PMID: 18989230 DOI: 10.1097/QAI.0b013e318189a794] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
34 Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006;20:2043-50. [PMID: 17053350 DOI: 10.1097/01.aids.0000247574.33998.03] [Cited by in Crossref: 193] [Cited by in F6Publishing: 172] [Article Influence: 12.1] [Reference Citation Analysis]
35 Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Hou N, Owens DK, Desai M. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One 2013;8:e59551. [PMID: 23555704 DOI: 10.1371/journal.pone.0059551] [Cited by in Crossref: 133] [Cited by in F6Publishing: 131] [Article Influence: 14.8] [Reference Citation Analysis]
36 Freiberg MS, So-Armah K. HIV and Cardiovascular Disease: We Need a Mechanism, and We Need a Plan. J Am Heart Assoc 2016;4:e003411. [PMID: 27013540 DOI: 10.1161/JAHA.116.003411] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
37 Dubé MP, Gorski JC, Shen C. Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. Cardiovasc Toxicol 2008;8:15-22. [PMID: 18172783 DOI: 10.1007/s12012-007-9010-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
38 Jung IY, Rupasinghe D, Woolley I, O'Connor CC, Giles M, Azwa RI, Choi JY; IeDEA Asia-Pacific. Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific. J Int AIDS Soc 2019;22:e25219. [PMID: 30615271 DOI: 10.1002/jia2.25219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
39 . 8.0 Antiretroviral therapy in specific populations: BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;13:57-81. [DOI: 10.1111/j.1468-1293.2012.01029_9.x] [Reference Citation Analysis]
40 Bloomfield GS, Hogan JW, Keter A, Holland TL, Sang E, Kimaiyo S, Velazquez EJ. Blood pressure level impacts risk of death among HIV seropositive adults in Kenya: a retrospective analysis of electronic health records. BMC Infect Dis 2014;14:284. [PMID: 24886474 DOI: 10.1186/1471-2334-14-284] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
41 de Gaetano Donati K, Cauda R, Iacoviello L. HIV Infection, Antiretroviral Therapy and Cardiovascular Risk. Mediterr J Hematol Infect Dis 2010;2:e2010034. [PMID: 21776340 DOI: 10.4084/MJHID.2010.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
42 Colotto M, Renzi A, Durante C. Into the wardrobe of Narnia: beyond HIV infection a world of cardiovascular risk. BMJ Case Rep 2012;2012:bcr2012006230. [PMID: 22805737 DOI: 10.1136/bcr-2012-006230] [Reference Citation Analysis]
43 Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB; Canadian Co-infection Cohort Study Investigators. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 2010;24:1857-65. [PMID: 20479633 DOI: 10.1097/QAD.0b013e32833adbb5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
44 Tasca KI, Fagundes Vidal VVM, Martinez Manfio V, Naime Barbosa A, de Souza LDR. Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA. J Appl Biomed 2021;19:73-82. [PMID: 34907718 DOI: 10.32725/jab.2021.002] [Reference Citation Analysis]
45 Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, Ganz P, Hsue PY. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010;24:1897-905. [PMID: 20543654 DOI: 10.1097/QAD.0b013e32833bee44] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
46 Ryom L, Lundgren JD, Law M, Kirk O, El-Sadr W, Bonnet F, Weber R, Fontas E, Monforte AD, Phillips A, Reiss P, de Wit S, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group. Serious clinical events in HIV-positive persons with chronic kidney disease. AIDS 2019;33:2173-88. [PMID: 31385862 DOI: 10.1097/QAD.0000000000002331] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
47 Bayard C, Ledergerber B, Flepp M, Lecompte T, Moulin E, Hoffmann M, Weber R, Staehelin C, Di Benedetto C, Fux CA, Tarr PE, Hasse B; Swiss HIV Cohort Study . Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. Open Forum Infect Dis 2017;4:ofx177. [PMID: 29026869 DOI: 10.1093/ofid/ofx177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
48 Mangili A, Ahmad R, Wolfert RL, Kuvin J, Polak JF, Karas RH, Wanke CA. Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients. Clin Infect Dis 2014;58:893-900. [PMID: 24336757 DOI: 10.1093/cid/cit815] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
49 Edward AO, Oladayo AA, Omolola AS, Adetiloye AA, Adedayo PA. Prevalence of traditional cardiovascular risk factors and evaluation of cardiovascular risk using three risk equations in nigerians living with human immunodeficiency virus. N Am J Med Sci 2013;5:680-8. [PMID: 24404550 DOI: 10.4103/1947-2714.123251] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
50 Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte Ad, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW; Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537-48. [PMID: 20453631 DOI: 10.1097/QAD.0b013e32833a0918] [Cited by in Crossref: 212] [Cited by in F6Publishing: 201] [Article Influence: 17.7] [Reference Citation Analysis]
51 Freiberg MS, Leaf DA, Goulet JL, Goetz MB, Oursler KK, Gibert CL, Rodriguez-Barradas MC, Butt AA, Justice AC. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med 2009;24:334-40. [PMID: 19127386 DOI: 10.1007/s11606-008-0891-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
52 Ssinabulya I, Kayima J, Longenecker C, Luwedde M, Semitala F, Kambugu A, Ameda F, Bugeza S, McComsey G, Freers J, Nakanjako D. Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. PLoS One 2014;9:e89537. [PMID: 24586854 DOI: 10.1371/journal.pone.0089537] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
53 Wilkin TJ, Gulick RM. CCR5 antagonism in HIV infection: current concepts and future opportunities. Annu Rev Med 2012;63:81-93. [PMID: 22034870 DOI: 10.1146/annurev-med-052010-145454] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
54 Lamers SL, Salemi M, Galligan DC, Morris A, Gray R, Fogel G, Zhao L, McGrath MS. Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain. J Neurovirol 2010;16:230-41. [PMID: 20367240 DOI: 10.3109/13550281003735709] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
55 Johnsen S, Dolan SE, Fitch KV, Kanter JR, Hemphill LC, Connelly JM, Lees RS, Lee H, Grinspoon S. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006;91:4916-24. [PMID: 17003092 DOI: 10.1210/jc.2006-1140] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis]
56 Kim RJ, Rutstein RM. Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients. Paediatr Drugs 2010;12:187-99. [PMID: 20481647 DOI: 10.2165/11532520-000000000-00000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
57 Garcia JM, Dong Y, Richardson P, Kramer JR, Hartman CM, Royse K, White DL, Chiao EY. Effect of HIV and antiretroviral therapy use on body weight changes in a cohort of U.S. veterans living with and without HIV. HIV Med 2022. [PMID: 35929183 DOI: 10.1111/hiv.13366] [Reference Citation Analysis]
58 Akhtar-Khaleel WZ, Cook RL, Shoptaw S, Surkan PJ, Teplin LA, Stall R, Beyth RJ, Manini TM, Plankey M. Long-Term Cigarette Smoking Trajectories Among HIV-Seropositive and Seronegative MSM in the Multicenter AIDS Cohort Study. AIDS Behav 2016;20:1713-21. [PMID: 26922718 DOI: 10.1007/s10461-016-1343-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
59 Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther 2012;9:31. [PMID: 23095661 DOI: 10.1186/1742-6405-9-31] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
60 Pacheco AG, Tuboi SH, May SB, Moreira LF, Ramadas L, Nunes EP, Merçon M, Faulhaber JC, Harrison LH, Schechter M. Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2009;51:624-30. [PMID: 19430304 DOI: 10.1097/QAI.0b013e3181a4ecf5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
61 Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007;12:149-62. [PMID: 17503657 DOI: 10.1177/135965350701200214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, Havlir DV, Hsue PY. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012;59:1891-6. [PMID: 22595409 DOI: 10.1016/j.jacc.2012.02.024] [Cited by in Crossref: 164] [Cited by in F6Publishing: 158] [Article Influence: 16.4] [Reference Citation Analysis]
63 Lau B, Gange SJ, Moore RD. Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses 2007;23:769-76. [PMID: 17604539 DOI: 10.1089/aid.2006.0171] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
64 Diaz CM, Segura ER, Luz PM, Clark JL, Ribeiro SR, De Boni R, Eksterman L, Moreira R, Currier JS, Veloso VG, Grinsztejn B, Lake JE. Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study. BMC Infect Dis 2016;16:376. [PMID: 27503230 DOI: 10.1186/s12879-016-1735-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
65 Zhou C. Novel functions of PXR in cardiometabolic disease. Biochim Biophys Acta 2016;1859:1112-20. [PMID: 26924429 DOI: 10.1016/j.bbagrm.2016.02.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
66 Soares C, Samara A, Yuyun MF, Echouffo-Tcheugui JB, Masri A, Samara A, Morrison AR, Lin N, Wu WC, Erqou S. Coronary Artery Calcification and Plaque Characteristics in People Living With HIV: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2021;10:e019291. [PMID: 34585590 DOI: 10.1161/JAHA.120.019291] [Reference Citation Analysis]
67 Sloan DD, Lam CY, Irrinki A, Liu L, Tsai A, Pace CS, Kaur J, Murry JP, Balakrishnan M, Moore PA, Johnson S, Nordstrom JL, Cihlar T, Koenig S. Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells. PLoS Pathog 2015;11:e1005233. [PMID: 26539983 DOI: 10.1371/journal.ppat.1005233] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 9.7] [Reference Citation Analysis]
68 Durand M, Chartrand-Lefebvre C, Baril JG, Trottier S, Trottier B, Harris M, Walmsley S, Conway B, Wong A, Routy JP, Kovacs C, MacPherson PA, Monteith KM, Mansour S, Thanassoulis G, Abrahamowicz M, Zhu Z, Tsoukas C, Ancuta P, Bernard N, Tremblay CL; investigators of the Canadian HIV and Aging Cohort Study. The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol. BMC Infect Dis 2017;17:611. [PMID: 28893184 DOI: 10.1186/s12879-017-2692-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
69 Guardiola M, Echeverria P, González M, Vallvé JC, Puig J, Clotet B, Ribalta J, Negredo E. Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. AIDS Res Hum Retroviruses 2015;31:882-8. [PMID: 26101956 DOI: 10.1089/AID.2015.0061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
70 Han SN, Sun XY, Zhang Z, Zhang LR. The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane. Acta Pharmacol Sin 2015;36:454-62. [PMID: 25832426 DOI: 10.1038/aps.2014.165] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
71 Feinstein MJ, Bogorodskaya M, Bloomfield GS, Vedanthan R, Siedner MJ, Kwan GF, Longenecker CT. Cardiovascular Complications of HIV in Endemic Countries. Curr Cardiol Rep 2016;18:113. [PMID: 27730474 DOI: 10.1007/s11886-016-0794-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
72 Akhigbe RE, Hamed MA. Co-administration of HAART and antikoch triggers cardiometabolic dysfunction through an oxidative stress-mediated pathway. Lipids Health Dis 2021;20:62. [PMID: 34225751 DOI: 10.1186/s12944-021-01493-x] [Reference Citation Analysis]
73 Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. When should antiretroviral therapy for HIV be started? BMJ 2007;334:76-8. [PMID: 17218713 DOI: 10.1136/bmj.39064.406389.94] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 3.5] [Reference Citation Analysis]
74 Gómez-Berrocal A, De Los Santos-Gil I, Abad-Pérez D, Gutiérrez-Liarte Á, Ibáñez-Sanz P, Sanz-Sanz J, Suárez C. Ambulatory Blood Pressure Monitoring in HIV-Infected Patients: Usefulness for Cardiovascular Risk Assessment. J Int Assoc Provid AIDS Care 2020;19:2325958220935693. [PMID: 32812480 DOI: 10.1177/2325958220935693] [Reference Citation Analysis]
75 Koethe JR, Moore RD, Wagner KR. Physician specialization and women's primary care services in an urban HIV clinic. AIDS Patient Care STDS 2008;22:373-80. [PMID: 18373414 DOI: 10.1089/apc.2007.0032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
76 Lipshultz SE, Sasaki N, Thompson B, Eidem BW, Cheng I, Colan SD, O'Brien SE, Amdani S, Shearer WT, Orav EJ, Miller TL, Wilkinson JD. Left ventricular diastolic dysfunction in HIV-uninfected infants exposed in utero to antiretroviral therapy. AIDS 2020;34:529-37. [PMID: 31764073 DOI: 10.1097/QAD.0000000000002443] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
77 Ryom L, Mocroft A, Kirk O, Reiss P, Ross M, Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD; D:A:D study group. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. AIDS 2017;31:1261-70. [PMID: 28492392 DOI: 10.1097/QAD.0000000000001464] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
78 Smith JM, Flexner C. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. AIDS 2017;31 Suppl 2:S173-84. [PMID: 28471948 DOI: 10.1097/QAD.0000000000001401] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
79 Chow DC, Stein JH, Seto TB, Mitchell C, Sriratanaviriyakul N, Grandinetti A, Gerschenson M, Shiramizu B, Souza S, Shikuma C. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. AIDS 2010;24:1019-23. [PMID: 20216298 DOI: 10.1097/QAD.0b013e3283383016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
80 Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol 2010;4:279-87. [PMID: 20824151 DOI: 10.1016/j.jacl.2010.04.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
81 Lazar JM, Wu X, Shi Q, Kagame A, Cohen M, Binagwaho A, Munyakazi L, Salciccioli L, Shi D, Anastos K. Arterial wave reflection in HIV-infected and HIV-uninfected Rwandan women. AIDS Res Hum Retroviruses 2009;25:877-82. [PMID: 19689195 DOI: 10.1089/aid.2008.0269] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
82 Wagle A, Goerlich E, Post WS, Woldu B, Wu KC, Hays AG. HIV and Global Cardiovascular Health. Curr Cardiol Rep 2022. [PMID: 35802233 DOI: 10.1007/s11886-022-01741-1] [Reference Citation Analysis]
83 Strijdom H, De Boever P, Walzl G, Essop MF, Nawrot TS, Webster I, Westcott C, Mashele N, Everson F, Malherbe ST, Stanley K, Kessler HH, Stelzl E, Goswami N. Cardiovascular risk and endothelial function in people living with HIV/AIDS: design of the multi-site, longitudinal EndoAfrica study in the Western Cape Province of South Africa. BMC Infect Dis 2017;17:41. [PMID: 28061822 DOI: 10.1186/s12879-016-2158-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
84 Mak IT, Kramer JH, Chen X, Chmielinska JJ, Spurney CF, Weglicki WB. Mg supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress, and cardiac dysfunction in rats. Am J Physiol Regul Integr Comp Physiol 2013;305:R1102-11. [PMID: 24049113 DOI: 10.1152/ajpregu.00268.2013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
85 Joy T, Keogh HM, Hadigan C, Lee H, Dolan SE, Fitch K, Liebau J, Lo J, Johnsen S, Hubbard J, Anderson EJ, Grinspoon S. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS 2007;21:1591-600. [PMID: 17630554 DOI: 10.1097/QAD.0b013e32823644ff] [Cited by in Crossref: 41] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
86 Lebech AM, Kristoffersen US, Wiinberg N, Kofoed K, Andersen O, Hesse B, Petersen CL, Gerstoft J, Kjaer A. Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. Eur J Nucl Med Mol Imaging 2008;35:2049-58. [PMID: 18661131 DOI: 10.1007/s00259-008-0846-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
87 Molino CGRC, Carnevale RC, Rodrigues AT, Moriel P, Mazzola PG. HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems. Saudi Pharm J 2017;25:724-33. [PMID: 28725145 DOI: 10.1016/j.jsps.2016.11.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
88 Ye Y, Zeng Y, Li X, Zhang S, Fang Q, Luo L, Qiu Z, Han Y, Li T. HIV infection: an independent risk factor of peripheral arterial disease. J Acquir Immune Defic Syndr 2010;53:276-8. [PMID: 20104124 DOI: 10.1097/QAI.0b013e3181ba1c31] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
89 Premeaux TA, Javandel S, Hosaka KRJ, Greene M, Therrien N, Allen IE, Corley MJ, Valcour VG, Ndhlovu LC. Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy. Front Immunol 2020;11:1321. [PMID: 32695109 DOI: 10.3389/fimmu.2020.01321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
90 Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, Gatell J, Clotet B, Phillips AN, Lundgren JD; EuroSIDA Study Group. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005;19:2117-25. [PMID: 16284461 DOI: 10.1097/01.aids.0000194799.43799.ea] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 5.2] [Reference Citation Analysis]
91 Blackstock OJ, Wang KH, Fiellin DA. State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. J Gen Intern Med 2011;26:1426-33. [PMID: 21837376 DOI: 10.1007/s11606-011-1807-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
92 Neumann T, Lülsdorf KA, Krings P, Reinsch N, Erbel R. [Coronary artery disease in HIV-infected subjects. Results of 101 coronary angiographies]. Herz 2011;36:18-23. [PMID: 21181097 DOI: 10.1007/s00059-010-3410-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Mallon PW, Miller J, Kovacic JC, Kent-Hughes J, Norris R, Samaras K, Feneley MP, Cooper DA, Carr A. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. AIDS 2006;20:1003-10. [PMID: 16603852 DOI: 10.1097/01.aids.0000222072.37749.5a] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 4.4] [Reference Citation Analysis]
94 Masiá M, Padilla S, García JA, García-Abellán J, Fernández M, Bernardino I, Montero M, Peraire J, Pernas B, Gutiérrez F. Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004-2015. PLoS One 2019;14:e0215507. [PMID: 31026289 DOI: 10.1371/journal.pone.0215507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
95 McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004;18:1753-68. [PMID: 15316336 DOI: 10.1097/00002030-200409030-00004] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
96 Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology 2011;76:444-50. [PMID: 21248273 DOI: 10.1212/WNL.0b013e31820a0cfc] [Cited by in Crossref: 101] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
97 Spagnolo-Allende A, Gutierrez J. Role of Brain Arterial Remodeling in HIV-Associated Cerebrovascular Outcomes. Front Neurol 2021;12:593605. [PMID: 34239489 DOI: 10.3389/fneur.2021.593605] [Reference Citation Analysis]
98 Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis 2013;56:870-9. [PMID: 23090925 DOI: 10.1093/cid/cis919] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
99 Mallon PW. Antiretroviral therapy and dyslipidaemia: unlocking the code. PLoS Med 2006;3:e85. [PMID: 16420104 DOI: 10.1371/journal.pmed.0030085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
100 d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Møller N; Writing Committee of the D:A:D: Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004;18:1811-7. [PMID: 15316342 DOI: 10.1097/00002030-200409030-00010] [Cited by in Crossref: 173] [Cited by in F6Publishing: 143] [Article Influence: 9.6] [Reference Citation Analysis]
101 Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7:e44454. [PMID: 22970224 DOI: 10.1371/journal.pone.0044454] [Cited by in Crossref: 352] [Cited by in F6Publishing: 356] [Article Influence: 35.2] [Reference Citation Analysis]
102 Parienti J, Verdon R. Névirapine et risque cardiovasculaire. Médecine et Maladies Infectieuses 2010;40:499-505. [DOI: 10.1016/j.medmal.2010.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
103 Freiberg MS, Cheng DM, Kraemer KL, Saitz R, Kuller LH, Samet JH. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS 2007;21:193-7. [PMID: 17197810 DOI: 10.1097/QAD.0b013e3280118a0d] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
104 Chastain DB, Henderson H, Stover KR. Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J 2015;9:23-37. [PMID: 25866592 DOI: 10.2174/1874613601509010023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
105 van den Dries LWJ, Wagener MN, Jiskoot LC, Visser M, Robertson KR, Adriani KS, van Gorp ECM. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study. AIDS Patient Care STDS 2017;31:329-34. [PMID: 28753395 DOI: 10.1089/apc.2017.0038] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
106 Mondal P, Aljizeeri A, Small G, Malhotra S, Harikrishnan P, Affandi JS, Buechel RR, Dwivedi G, Al-Mallah MH, Jain D. Coronary artery disease in patients with human immunodeficiency virus infection. J Nucl Cardiol 2021;28:510-30. [PMID: 32820424 DOI: 10.1007/s12350-020-02280-4] [Reference Citation Analysis]
107 Chaudhry AA, Gifford AL, Cofrancesco Jr. J, Sosman J, Berkenblit G, Sullivan LE. Update in HIV Medicine for the Generalist. J GEN INTERN MED 2009;24:276-82. [DOI: 10.1007/s11606-008-0851-2] [Reference Citation Analysis]
108 Moadel AB, Bernstein SL, Mermelstein RJ, Arnsten JH, Dolce EH, Shuter J. A randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. J Acquir Immune Defic Syndr 2012;61:208-15. [PMID: 22732470 DOI: 10.1097/QAI.0b013e3182645679] [Cited by in Crossref: 68] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
109 Mtshali Z, Moodley J, Naicker T. An Insight into the Angiogenic and Lymphatic Interplay in Pre-eclampsia Comorbid with HIV Infection. Curr Hypertens Rep 2020;22:35. [PMID: 32200445 DOI: 10.1007/s11906-020-01040-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV AIDS (Auckl) 2012;4:117-24. [PMID: 22893751 DOI: 10.2147/HIV.S32321] [Cited by in Crossref: 29] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
111 Raj SR, Stein CM, Saavedra PJ, Roden DM. Cardiovascular effects of noncardiovascular drugs. Circulation 2009;120:1123-32. [PMID: 19770411 DOI: 10.1161/CIRCULATIONAHA.107.728576] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
112 Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc 2011;8:313-9. [PMID: 21653534 DOI: 10.1513/pats.201009-058WR] [Cited by in Crossref: 92] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
113 Lopes KG, Farinatti P, Lopes GO, Paz GA, Bottino DA, Oliveira RB, Bouskela E, Borges JP. Muscle mass, strength, bone mineral density and vascular function in middle-aged people living with HIV vs. age-matched and older controls. Braz J Infect Dis 2021;25:101654. [PMID: 34826379 DOI: 10.1016/j.bjid.2021.101654] [Reference Citation Analysis]
114 Curlin ME, Iyer S, Mittler JE. Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput Biol 2007;3:e133. [PMID: 17630827 DOI: 10.1371/journal.pcbi.0030133] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
115 Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petoumenos K, Wentworth D, Winston A, Wolfson J, Neaton JD; INSIGHT SMART Study Group., ESPRIT Study Group. Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy. PLoS One 2014;9:e95061. [PMID: 24728071 DOI: 10.1371/journal.pone.0095061] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
116 Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus Nordwall J, Johnson M, Vjecha MJ, Kelleher AD, Emery S. Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. Sci Rep 2017;7:10934. [PMID: 28883647 DOI: 10.1038/s41598-017-11405-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
117 Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007;166:13-21. [PMID: 16896646 DOI: 10.1007/s00431-006-0193-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
118 Lo J. Dyslipidemia and lipid management in HIV-infected patients. Curr Opin Endocrinol Diabetes Obes 2011;18:144-7. [PMID: 21297466 DOI: 10.1097/MED.0b013e328344556e] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
119 Puertas MC, Gómez-Mora E, Santos JR, Moltó J, Urrea V, Morón-López S, Hernández-Rodríguez A, Marfil S, Martínez-Bonet M, Matas L, Muñoz-Fernández MA, Clotet B, Blanco J, Martinez-Picado J. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. J Antimicrob Chemother 2018;73:1940-8. [PMID: 29635527 DOI: 10.1093/jac/dky106] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
120 Amado Costa L, Almeida AG. Cardiovascular disease associated with human immunodeficiency virus: A review. Revista Portuguesa de Cardiologia (English Edition) 2015;34:479-91. [DOI: 10.1016/j.repce.2015.06.008] [Reference Citation Analysis]
121 Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, Guffanti M, Gianotti N, Bigoloni A, Lazzarin A, Castagna A. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol 2012;27:657-65. [PMID: 22722952 DOI: 10.1007/s10654-012-9707-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
122 Leyes P, Martínez E, Larrousse M, Cofán M, Trabal J, Pérez-Heras AM, Forga MT, Ros E. Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial. BMC Infect Dis 2014;14:497. [PMID: 25209653 DOI: 10.1186/1471-2334-14-497] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
123 Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008;22:1719-28. [PMID: 18690162 DOI: 10.1097/QAD.0b013e32830a5058] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
124 Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, Ross M, Morlat P, Andreas Fux C, Fontas E, De Wit S, D'Arminio Monforte A, El-Sadr W, Phillips A, Ingrid Hatleberg C, Sabin C, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis 2019;220:1629-34. [PMID: 31504669 DOI: 10.1093/infdis/jiz369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
125 Gopal M, Bhaskaran A, Khalife WI, Barbagelata A. Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. Curr Cardiol Rev 2009;5:149-54. [PMID: 20436855 DOI: 10.2174/157340309788166705] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
126 Pacek LR, Crum RM. A Review of the Literature Concerning HIV and Cigarette Smoking: Morbidity and Mortality, Associations with Individual- and Social-Level Characteristics, and Smoking Cessation Efforts. Addict Res Theory 2015;23:10-23. [PMID: 28529471 DOI: 10.3109/16066359.2014.920013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
127 Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, Williams CM, Phair JP; Multicenter AIDS Cohort Study. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005;19:953-60. [PMID: 15905677 DOI: 10.1097/01.aids.0000171410.76607.f8] [Cited by in Crossref: 221] [Cited by in F6Publishing: 222] [Article Influence: 13.0] [Reference Citation Analysis]
128 Gandhi NR, Tate JP, Rodriguez-Barradas MC, Rimland D, Goetz MB, Gibert C, Brown ST, Mattocks K, Justice AC. Validation of an algorithm to identify antiretroviral-naïve status at time of entry into a large, observational cohort of HIV-infected patients. Pharmacoepidemiol Drug Saf 2013;22:1019-25. [PMID: 23836591 DOI: 10.1002/pds.3476] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
129 Bąkowska E, Cielniak I, Święcki P, Ignatowska A, Pulik P, Burkacka E, Horban A. HIV infection in ageing population Case report of three patients over 75 years old. HIV & AIDS Review 2008;7:21-5. [DOI: 10.1016/s1730-1270(10)60019-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
130 van Wijk JP, Cabezas MC. Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vasc Med 2012;2012:201027. [PMID: 21876813 DOI: 10.1155/2012/201027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
131 Frades I, Readhead B, Amadori L, Koplev S, Talukdar HA, Crane HM, Crane PK, Kovacic JC, Dudley JT, Giannarelli C, Björkegren JLM, Peter I. Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy. Circ Genom Precis Med 2019;12:e002390. [PMID: 31059280 DOI: 10.1161/CIRCGEN.118.002390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Kearney F, Moore AR, Donegan CF, Lambert J. The ageing of HIV: implications for geriatric medicine. Age Ageing 2010;39:536-41. [PMID: 20685813 DOI: 10.1093/ageing/afq083] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
133 Freiberg MS, McGinnis KA, Kraemer K, Samet JH, Conigliaro J, Curtis Ellison R, Bryant K, Kuller LH, Justice AC; VACS Project Team. The association between alcohol consumption and prevalent cardiovascular diseases among HIV-infected and HIV-uninfected men. J Acquir Immune Defic Syndr 2010;53:247-53. [PMID: 20009766 DOI: 10.1097/QAI.0b013e3181c6c4b7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
134 Kline ER, Sutliff RL. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 2008;56:752-69. [PMID: 18525451 DOI: 10.1097/JIM.0b013e3181788d15] [Cited by in Crossref: 63] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
135 Mussini C. Baseline HIV RNA and the when to start question: time to stop asking this question? AIDS 2006;20:1197-8. [PMID: 16691072 DOI: 10.1097/01.aids.0000226961.33213.8c] [Reference Citation Analysis]
136 Gyalrong-Steur M, Bogner JR, Seybold U. Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients. Eur J Med Res 2011;16:85-92. [PMID: 21463988 DOI: 10.1186/2047-783x-16-2-85] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
137 Pepin ME, Padgett LE, McDowell RE, Burg AR, Brahma MK, Holleman C, Kim T, Crossman D, Kutsch O, Tse HM, Wende AR, Habegger KM. Antiretroviral therapy potentiates high-fat diet induced obesity and glucose intolerance. Mol Metab 2018;12:48-61. [PMID: 29731256 DOI: 10.1016/j.molmet.2018.04.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
138 Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, Ubolyam S, Carr A, Ruxungtham K, Hirschel B, Ananworanich J; STACCATO Study Group. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009;23:929-39. [PMID: 19425222 DOI: 10.1097/qad.0b013e32832995fa] [Cited by in Crossref: 108] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
139 Stöllberger C, Armbruster C, Gmeinhart B, Finsterer J. Thrombosis of a drug-eluting stent after almost 2 years in an HIV-infected patient. AIDS 2007;21:1064-6. [PMID: 17457111 DOI: 10.1097/QAD.0b013e3280f6ceb9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010;10:183. [PMID: 20573187 DOI: 10.1186/1471-2334-10-183] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
141 Hansen L, Parker I, Sutliff RL, Platt MO, Gleason RL Jr. Endothelial dysfunction, arterial stiffening, and intima-media thickening in large arteries from HIV-1 transgenic mice. Ann Biomed Eng 2013;41:682-93. [PMID: 23180031 DOI: 10.1007/s10439-012-0702-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
142 Collins LF, Adekunle RO, Cartwright EJ. Metabolic Syndrome in HIV/HCV Co-infected Patients. Curr Treat Options Infect Dis 2019;11:351-71. [PMID: 32030090 DOI: 10.1007/s40506-019-00207-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Mutimura E, Crowther NJ, Stewart A, Cade WT. The human immunodeficiency virus and the cardiometabolic syndrome in the developing world: an African perspective. J Cardiometab Syndr 2008;3:106-10. [PMID: 18453811 DOI: 10.1111/j.1559-4572.2008.07584.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
144 Satchell CS, Cotter AG, O'Connor EF, Peace AJ, Tedesco AF, Clare A, Lambert JS, Sheehan GJ, Kenny D, Mallon PW. Platelet function and HIV: a case-control study. AIDS 2010;24:649-57. [PMID: 20177361 DOI: 10.1097/QAD.0b013e328336098c] [Cited by in Crossref: 54] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
145 Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012;2012:670957. [PMID: 22474480 DOI: 10.1155/2012/670957] [Cited by in Crossref: 101] [Cited by in F6Publishing: 105] [Article Influence: 10.1] [Reference Citation Analysis]
146 Martin-Iguacel R, Llibre JM, Friis-Moller N. Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now? Curr HIV/AIDS Rep 2015;12:375-87. [PMID: 26423407 DOI: 10.1007/s11904-015-0284-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
147 Nelson L, Fried M, Stewart K. HIV-infected patients: the risks of surgery. J Perioper Pract 2009;19:24-30. [PMID: 19260358 DOI: 10.1177/175045890901900103] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
148 Nahvi S, Cooperman NA. Review: the need for smoking cessation among HIV-positive smokers. AIDS Educ Prev 2009;21:14-27. [PMID: 19537951 DOI: 10.1521/aeap.2009.21.3_supp.14] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 6.1] [Reference Citation Analysis]
149 Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. J Infect Dis 2012;205 Suppl 3:S368-74. [PMID: 22577210 DOI: 10.1093/infdis/jis201] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
150 Choi H, Dey AK, Sharma G, Bhoite R, Burkholder G, Fedson S, Jneid H. Etiology and pathophysiology of heart failure in people with HIV. Heart Fail Rev 2021;26:497-505. [PMID: 33619685 DOI: 10.1007/s10741-020-10048-8] [Reference Citation Analysis]
151 Martínez E, López Bernaldo de Quirós JC, Miralles C, Podzamczer D. Considerations on the increase in blood pressure among antiretroviral-naive patients starting HAART. AIDS 2007;21:384-6. [PMID: 17255753 DOI: 10.1097/QAD.0b013e328011daef] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
152 Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus J, Wentworth D, Johnson M, Vjecha MJ, Kelleher AD, Emery S; INSIGHT ESPRIT and SMART Study Groups. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS One 2015;10:e0139981. [PMID: 26465293 DOI: 10.1371/journal.pone.0139981] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
153 Seaberg EC, Benning L, Sharrett AR, Lazar JM, Hodis HN, Mack WJ, Siedner MJ, Phair JP, Kingsley LA, Kaplan RC. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke. 2010;41:2163-2170. [PMID: 20798374 DOI: 10.1161/strokeaha.110.583856] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
154 Stebbing J, Bower M, Holmes P, Gazzard B, Nelson M. A single centre cohort experience with a new once daily antiretroviral drug. Postgrad Med J 2006;82:343-6. [PMID: 16679474 DOI: 10.1136/pgmj.2006.044867] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
155 Nagaraja V, Terriquez JA, Gavini H, Jha L, Klotz SA. Pulmonary Embolism Mimicking Pneumonia in a HIV Patient. Case Rep Med 2010;2010:394546. [PMID: 20589218 DOI: 10.1155/2010/394546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
156 Domingo P, Mateo MG, Villarroya J, Cereijo R, Torres F, Domingo JC, Campderrós L, Gallego-Escuredo JM, Gutierrez MDM, Mur I, Corbacho N, Vidal F, Villarroya F, Giralt M. Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy. J Clin Med 2022;11:549. [PMID: 35160008 DOI: 10.3390/jcm11030549] [Reference Citation Analysis]
157 Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, Anastos K, Tien PC, Sharrett AR, Hodis HN. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008;22:1615-24. [PMID: 18670221 DOI: 10.1097/QAD.0b013e328300581d] [Cited by in Crossref: 195] [Cited by in F6Publishing: 133] [Article Influence: 13.9] [Reference Citation Analysis]
158 Jaworowski A, Hearps AC, Angelovich TA, Hoy JF. How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy. Front Immunol 2019;10:1378. [PMID: 31275317 DOI: 10.3389/fimmu.2019.01378] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
159 The Respond Study Group. How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium. Microorganisms 2020;8:E1164. [PMID: 32752044 DOI: 10.3390/microorganisms8081164] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
160 Alvarez A, Orden S, Andújar I, Collado-Diaz V, Núñez-Delgado S, Galindo MJ, Estrada V, Apostolova N, Esplugues JV. Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation. AIDS 2017;31:1781-95. [PMID: 28537935 DOI: 10.1097/QAD.0000000000001547] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 6.2] [Reference Citation Analysis]
161 Hirigo AT, Gutema S, Eifa A, Ketema W. Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus. SAGE Open Med Case Rep 2022;10:2050313X221079444. [PMID: 35223037 DOI: 10.1177/2050313X221079444] [Reference Citation Analysis]
162 Calza L, Manfredi R, Colangeli V, Tampellini L, Sebastiani T, Pocaterra D, Chiodo F. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005;19:1051-8. [PMID: 15958836 DOI: 10.1097/01.aids.0000174451.78497.8f] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 4.6] [Reference Citation Analysis]
163 Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, Cavert WP, Henry WK, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008;22:841-8. [PMID: 18427202 DOI: 10.1097/QAD.0b013e3282f7cb76] [Cited by in Crossref: 270] [Cited by in F6Publishing: 159] [Article Influence: 19.3] [Reference Citation Analysis]
164 Lawal IO, Ankrah AO, Stoltz AC, Sathekge MM. Radionuclide imaging of inflammation in atherosclerotic vascular disease among people living with HIV infection: current practice and future perspective. Eur J Hybrid Imaging 2019;3:5. [PMID: 34191183 DOI: 10.1186/s41824-019-0053-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
165 Hammoud DA, Sinharay S, Steinbach S, Wakim PG, Geannopoulos K, Traino K, Dey AK, Tramont E, Rapoport SI, Snow J, Mehta NN, Smith BR, Nath A. Global and regional brain hypometabolism on FDG-PET in treated HIV-infected individuals. Neurology 2018;91:e1591-601. [PMID: 30258017 DOI: 10.1212/WNL.0000000000006398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
166 Dau B, Holodniy M. The Relationship Between HIV Infection and Cardiovascular Disease. Curr Cardiol Rev 2008;4:203-18. [PMID: 19936197 DOI: 10.2174/157340308785160589] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
167 Wise L, Parkinson J, Raine J, Breckenridge A. New approaches to drug safety: a pharmacovigilance tool kit. Nat Rev Drug Discov 2009;8:779-82. [PMID: 19763106 DOI: 10.1038/nrd3002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
168 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143. [PMID: 30586774 DOI: 10.1161/cir.0000000000000625] [Cited by in Crossref: 250] [Cited by in F6Publishing: 310] [Article Influence: 62.5] [Reference Citation Analysis]
169 Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS 2007;21:479-91. [PMID: 17651029 DOI: 10.1089/apc.2006.0150] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
170 Baker JV, Henry WK, Neaton JD. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS 2009;4:176-82. [PMID: 19532047 DOI: 10.1097/COH.0b013e328329c62f] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
171 Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, Burkholder GA, Mathews WC, Silverberg MJ, Sterling TR, Heckbert SR, Budoff MJ, Van Rompaey S, Delaney JAC, Wong C, Tong W, Palella FJ, Elion RA, Martin JN, Brooks JT, Jacobson LP, Eron JJ, Justice AC, Freiberg MS, Klein DB, Post WS, Saag MS, Moore RD, Crane HM. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr 2017;75:568-76. [PMID: 28520615 DOI: 10.1097/QAI.0000000000001450] [Cited by in Crossref: 68] [Cited by in F6Publishing: 49] [Article Influence: 13.6] [Reference Citation Analysis]
172 Gebo KA. Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging health 2008;4:615-27. [PMID: 19915688 DOI: 10.2217/1745509X.4.6.615] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
173 Malavika Bugge P, Thangaraj Saravana Kumar R, B. V. S L; Assistant Professor, Department of Pharmacy Practice, NOVA College of Pharmaceutical Education and Research, JNTUK, Vijayawada - 521456, Andhra Pradesh, India, Associate Professor, Department of Pharmacy Practice, Annamalai University, Chidambaram - 608002, Tamil Nadu, India, Associate Professor, Department of Pharmacy, Mallareddy College of Pharmacy, Osmania University, Hyderabad - 500007, Telangana, India. Estimation of the Rationality of ARV therapy in South India. Asian Journal of Pharmaceutical Research and Health Care 2021;13:115-22. [DOI: 10.18311/ajprhc/2021/26712] [Reference Citation Analysis]
174 Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011;25:885-97. [PMID: 21422987 DOI: 10.1097/QAD.0b013e3283467041] [Cited by in Crossref: 92] [Cited by in F6Publishing: 61] [Article Influence: 8.4] [Reference Citation Analysis]
175 Strategies for Management of Anti-Retroviral Therapy/INSIGHT., DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-24. [PMID: 18753925 DOI: 10.1097/QAD.0b013e32830fe35e] [Cited by in Crossref: 239] [Cited by in F6Publishing: 108] [Article Influence: 17.1] [Reference Citation Analysis]
176 Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, Grinspoon SK, Levin J, Longenecker CT, Post WS. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation 2019;140:e98-e124. [PMID: 31154814 DOI: 10.1161/CIR.0000000000000695] [Cited by in Crossref: 123] [Cited by in F6Publishing: 66] [Article Influence: 41.0] [Reference Citation Analysis]
177 Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, Neau D, Cazanave C, Pellegrin JL, Dabis F, Morlat P, Chêne G; GECSA study group. Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort. PLoS One 2014;9:e102671. [PMID: 25076050 DOI: 10.1371/journal.pone.0102671] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
178 Lloyd-Richardson EE, Stanton CA, Papandonatos GD, Shadel WG, Stein M, Tashima K, Flanigan T, Morrow K, Neighbors C, Niaura R. Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. Addiction 2009;104:1891-900. [PMID: 19719796 DOI: 10.1111/j.1360-0443.2009.02623.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 7.0] [Reference Citation Analysis]
179 Ryom L, Lundgren JD, Reiss P, Ross M, Kirk O, Fux CA, Morlat P, Fontas E, Smith C, De Wit S, d'Arminio Monforte A, El Sadr W, Hatleberg C, Phillips A, Sabin C, Law M, Mocroft A. The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. J Infect Dis 2021;223:632-7. [PMID: 32640015 DOI: 10.1093/infdis/jiaa396] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Krikke M, Tesselaar K, Arends JE, Drylewicz J, Otto SA, van Lelyveld SF, Visseren FJ, Hoepelman AI. Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study. Infect Dis Ther 2016;5:389-404. [PMID: 27300170 DOI: 10.1007/s40121-016-0115-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
181 Trevillyan JM, Wong G, Puls R, Petoumenos K, Emery S, Mellett NA, Mundra PA, Meikle PJ, Hoy JF; ALTAIR Study Group. Changes in plasma lipidome following initiation of antiretroviral therapy. PLoS One 2018;13:e0202944. [PMID: 30157268 DOI: 10.1371/journal.pone.0202944] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
182 El-Bassel N, Jemmott JB 3rd, Landis JR, Pequegnat W, Wingood GM, Wyatt GE, Bellamy SL; National Institute of Mental Health Multisite HIV/STD Prevention Trial for African-American Couples Group. Intervention to influence behaviors linked to risk of chronic diseases: a multisite randomized controlled trial with African-American HIV-serodiscordant heterosexual couples. Arch Intern Med 2011;171:728-36. [PMID: 21518939 DOI: 10.1001/archinternmed.2011.136] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
183 Cofrancesco J Jr, Freedland E, McComsey G. Treatment options for HIV-associated central fat accumulation. AIDS Patient Care STDS 2009;23:5-18. [PMID: 19055407 DOI: 10.1089/apc.2008.0067] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
184 Stanley TL, Joy T, Hadigan CM, Liebau JG, Makimura H, Chen CY, Thomas BJ, Weise SB, Robbins GK, Grinspoon SK. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009;23:1349-57. [PMID: 19474651 DOI: 10.1097/QAD.0b013e32832ba904] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
185 Maritati M, Alessandro T, Zanotta N, Comar M, Bellini T, Sighinolfi L, Contini C. A comparison between different anti-retroviral therapy regimes on soluble inflammation markers: a pilot study. AIDS Res Ther 2020;17:61. [PMID: 33054784 DOI: 10.1186/s12981-020-00316-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Wang P, Xu J, Guo B, Wang JK, Gao L, Wang Q, Jing J, Cheng F. Changes in clinical indicators among human immunodeficiency virus patients who failed in antiretroviral therapy during 2004–2016 in Yunnan, China: an observational cohort study. Global Health Journal 2020;4:57-63. [DOI: 10.1016/j.glohj.2020.04.001] [Reference Citation Analysis]
187 Edwards NJ, Grill MF, Choi HA, Ko NU. Frequency and Risk Factors for Cerebral Arterial Disease in a HIV/AIDS Neuroimaging Cohort. Cerebrovasc Dis 2016;41:170-6. [PMID: 26751784 DOI: 10.1159/000442755] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
188 Meixner L, Hoffman J, Zwickl B, Goldman M, Whitely K, Conrad A, Fichtenbaum CJ, Hyc F, Spitz T, Shaw DD, Norris J, Stoudt S, Castro J, Colon L, Cavert WP, Fox KA, Dubé MP, Wu JW, Aberg JA, Deeg MA, Alston-smith BL, Mcgovern ME, Lee D, Shriver SL, Martinez AI, Greenwald M, Stein JH; for the AIDS Clinical Trials Group A5148 Study Team. Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148. Antiviral Therapy 2006;11:1081-90. [DOI: 10.1177/135965350601100802] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
189 Kim SS, Darwish S, Lee SA, Sprague C, DeMarco RF. A randomized controlled pilot trial of a smoking cessation intervention for US women living with HIV: telephone-based video call vs voice call. Int J Womens Health 2018;10:545-55. [PMID: 30288127 DOI: 10.2147/IJWH.S172669] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
190 de Almeida ER, Reiche EM, Kallaur AP, Flauzino T, Watanabe MA. The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism. Biomed Res Int. 2013;2013:836790. [PMID: 24319689 DOI: 10.1155/2013/836790] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
191 El Khoury P, Ghislain M, Villard EF, Le Goff W, Lascoux-Combe C, Yeni P, Meyer L, Vigouroux C, Goujard C, Guerin M. Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART. J Lipid Res 2015;56:692-702. [PMID: 25573889 DOI: 10.1194/jlr.M054510] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
192 Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: the D:A:D study. J Infect Dis 2011;204:521-5. [PMID: 21791653 DOI: 10.1093/infdis/jir329] [Reference Citation Analysis]
193 Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121:651-658. [PMID: 20100969 DOI: 10.1161/circulationaha.109.898585] [Cited by in Crossref: 134] [Cited by in F6Publishing: 81] [Article Influence: 11.2] [Reference Citation Analysis]
194 Pacheco AG, Tuboi SH, Faulhaber JC, Harrison LH, Schechter M. Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil. PLoS One 2008;3:e1531. [PMID: 18231611 DOI: 10.1371/journal.pone.0001531] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
195 Roman S, Mekheal N, Tal S, Michael P. More Than Just an Ulcer: A Case of HIV-Associated Iliac Aneurysms Presenting With a Leg Ulcer. Cureus 2021;13:e13203. [PMID: 33717743 DOI: 10.7759/cureus.13203] [Reference Citation Analysis]
196 Kristoffersen US, Lebech AM, Wiinberg N, Petersen CL, Hasbak P, Gutte H, Jensen GB, Hag AM, Ripa RS, Kjaer A. Silent ischemic heart disease and pericardial fat volume in HIV-infected patients: a case-control myocardial perfusion scintigraphy study. PLoS One 2013;8:e72066. [PMID: 23967275 DOI: 10.1371/journal.pone.0072066] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
197 Rao MN, Mulligan K, Tai V, Wen MJ, Dyachenko A, Weinberg M, Li X, Lang T, Grunfeld C, Schwarz JM, Schambelan M. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab 2010;95:4361-6. [PMID: 20610601 DOI: 10.1210/jc.2009-2502] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
198 Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, Steinhart C. A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infect Dis Ther 2018;7:183-95. [PMID: 29761330 DOI: 10.1007/s40121-018-0201-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
199 Hejazi N, Rajikan R, Choong CL, Sahar S. Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey. BMC Public Health 2013;13:758. [PMID: 23947428 DOI: 10.1186/1471-2458-13-758] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
200 Fichtenbaum CJ. Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Curr Infect Dis Rep 2011;13:94-101. [PMID: 21308460 DOI: 10.1007/s11908-010-0153-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
201 Boger MS, Shintani A, Redhage LA, Mitchell V, Haas DW, Morrow JD, Hulgan T. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr 2009;52:480-7. [PMID: 19911471 DOI: 10.1097/qai.0b013e3181b939e5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
202 Kovari H, Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, Pradier C, Dabis F, d'Arminio Monforte A, Smith C, de Wit S, Kirk O, Lundgren JD, Weber R. Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infect Dis 2016;3:ofw009. [PMID: 26925429 DOI: 10.1093/ofid/ofw009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
203 Volpe GE, Tang AM, Polak JF, Mangili A, Skinner SC, Wanke CA. Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort. J Acquir Immune Defic Syndr 2013;64:51-7. [PMID: 23945252 DOI: 10.1097/QAI.0b013e31829ed726] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
204 Calza DL, Manfredi R, Chiodo F. Cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Expert Opinion on Therapeutic Patents 2006;16:1497-516. [DOI: 10.1517/13543776.16.11.1497] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
205 Alves MD, Brites C, Sprinz E. HIV-associated lipodystrophy: a review from a Brazilian perspective. Ther Clin Risk Manag. 2014;10:559-566. [PMID: 25083134 DOI: 10.2147/tcrm.s35075] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
206 Tyagi M, Bukrinsky M. Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med. 2012;18:1096-1108. [PMID: 22692576 DOI: 10.2119/molmed.2012.00194] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
207 Cioe PA. Smoking Cessation Interventions in HIV-Infected Adults in North America: A Literature Review. J Addict Behav Ther Rehabil 2013;2:1000112. [PMID: 24839610 DOI: 10.4172/2324-9005.1000112] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
208 Choi J, Jeong Y, Han HS, Lee KH. Microdevices for examining immunological responses of single cells to HIV. Biosci Rep 2014;34:e00134. [PMID: 25028990 DOI: 10.1042/BSR20140097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
209 Enkhmaa B, Anuurad E, Zhang W, Abbuthalha A, Li XD, Dotterweich W, Pollard RB, Asmuth DM, Berglund L. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol 2013;33:387-92. [PMID: 23202367 DOI: 10.1161/ATVBAHA.112.300125] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
210 Gleason RL Jr, Caulk AW, Seifu D, Parker I, Vidakovic B, Getenet H, Assefa G, Amogne W. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. PLoS One 2015;10:e0117125. [PMID: 25915208 DOI: 10.1371/journal.pone.0117125] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
211 Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, Wohl D, Shlipak MG. Microalbuminuria in HIV infection. AIDS 2007;21:1003-9. [PMID: 17457094 DOI: 10.1097/QAD.0b013e3280d3587f] [Cited by in Crossref: 99] [Cited by in F6Publishing: 74] [Article Influence: 6.6] [Reference Citation Analysis]
212 Neesgaard B, Greenberg L, Miró JM, Grabmeier-pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F, Pelchen-matthews A, Mussini C, Castagna A, Pradier C, d'Arminio Monforte A, Vehreschild JJ, Sönnerborg A, Anne AV, Carr A, Bansi-matharu L, Lundgren JD, Garges H, Rogatto F, Zangerle R, Günthard HF, Rasmussen LD, Necsoi C, van der Valk M, Menozzi M, Muccini C, Peters L, Mocroft A, Ryom L. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. The Lancet HIV 2022. [DOI: 10.1016/s2352-3018(22)00094-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Sheth AN, Moore RD, Gebo KA. Provision of general and HIV-specific health maintenance in middle aged and older patients in an urban HIV clinic. AIDS Patient Care STDS 2006;20:318-25. [PMID: 16706706 DOI: 10.1089/apc.2006.20.318] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
214 Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrol 2014;15:51. [PMID: 24666792 DOI: 10.1186/1471-2369-15-51] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
215 van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1:e19. [PMID: 15526045 DOI: 10.1371/journal.pmed.0010019] [Cited by in Crossref: 170] [Cited by in F6Publishing: 157] [Article Influence: 9.4] [Reference Citation Analysis]
216 Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-18. [PMID: 19417580 DOI: 10.1097/QAD.0b013e32832b4377] [Cited by in Crossref: 187] [Cited by in F6Publishing: 91] [Article Influence: 14.4] [Reference Citation Analysis]
217 Lifson AR, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J; INSIGHT Cause of Death Writing Group. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials 2008;9:177-85. [PMID: 18547904 DOI: 10.1310/hct0903-177] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
218 Roozen GVT, Meel R, Peper J, Venter WDF, Barth RE, Grobbee DE, Klipstein-Grobusch K, Vos AG. Electrocardiographic and echocardiographic abnormalities in urban African people living with HIV in South Africa. PLoS One 2021;16:e0244742. [PMID: 33529208 DOI: 10.1371/journal.pone.0244742] [Reference Citation Analysis]
219 Latinovic O, Kuruppu J, Davis C, Le N, Heredia A. Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc. Clin Med Ther 2009;1:1497-510. [PMID: 19920876 DOI: 10.4137/cmt.s2365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
220 Schwartz RM, Mansoor A, Wilson TE, Anastos K, Everson-Rose SA, Golub ET, Goparaju L, Hessol NA, Mack WJ, Lazar J. Chronic depressive symptoms and Framingham coronary risk in HIV-infected and HIV-uninfected women. AIDS Care 2012;24:394-403. [PMID: 21902560 DOI: 10.1080/09540121.2011.608791] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
221 Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. AIDS 2013;27:2735-48. [PMID: 23842128 DOI: 10.1097/01.aids.0000432457.91228.f3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
222 El Moussaoui M, Lambert I, Maes N, Sauvage AS, Frippiat F, Meuris C, Uurlings F, Lecomte M, Léonard P, Fombellida K, Vaira D, Vercheval C, Moutschen M, Darcis G. Evolution of Drug Interactions With Antiretroviral Medication in People With HIV. Open Forum Infect Dis 2020;7:ofaa416. [PMID: 33204748 DOI: 10.1093/ofid/ofaa416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
223 Anuurad E, Semrad A, Berglund L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord 2009;7:401-10. [PMID: 19355810 DOI: 10.1089/met.2008.0096] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
224 Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013;207:1359-69. [PMID: 23382571 DOI: 10.1093/infdis/jit043] [Cited by in Crossref: 210] [Cited by in F6Publishing: 198] [Article Influence: 23.3] [Reference Citation Analysis]
225 Anuurad E, Bremer A, Berglund L. HIV protease inhibitors and obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:478-85. [PMID: 20717021 DOI: 10.1097/MED.0b013e32833dde87] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
226 Hadigan C. Diabetes, insulin resistance, and HIV. Curr Infect Dis Rep 2006;8:69-75. [PMID: 16448603 DOI: 10.1007/s11908-006-0037-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
227 Coll B, Aragonés G, Parra S, Alonso-Villaverde C, Masana L. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006;20:1675-7. [PMID: 16868453 DOI: 10.1097/01.aids.0000238418.43937.3b] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
228 Tyagi M, Iordanskiy S, Ammosova T, Kumari N, Smith K, Breuer D, Ilatovskiy AV, Kont YS, Ivanov A, Üren A, Kovalskyy D, Petukhov M, Kashanchi F, Nekhai S. Reactivation of latent HIV-1 provirus via targeting protein phosphatase-1. Retrovirology 2015;12:63. [PMID: 26178009 DOI: 10.1186/s12977-015-0190-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
229 Annamalai L, Westmoreland SV, Domingues HG, Walsh DG, Gonzalez RG, O'Neil SP. Myocarditis in CD8-depleted SIV-infected rhesus macaques after short-term dual therapy with nucleoside and nucleotide reverse transcriptase inhibitors. PLoS One 2010;5:e14429. [PMID: 21203448 DOI: 10.1371/journal.pone.0014429] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
230 Palios J, Kadoglou NP, Lampropoulos S. The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines. Exp Diabetes Res 2012;2012:103063. [PMID: 22203832 DOI: 10.1155/2012/103063] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
231 Bahrami H, Budoff M, Haberlen SA, Rezaeian P, Ketlogetswe K, Tracy R, Palella F, Witt MD, McConnell MV, Kingsley L, Post WS. Inflammatory Markers Associated With Subclinical Coronary Artery Disease: The Multicenter AIDS Cohort Study. J Am Heart Assoc 2016;5:e003371. [PMID: 27353609 DOI: 10.1161/JAHA.116.003371] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
232 Ferrara M, Umlauf A, Sanders C, Meyer JM, Allen McCutchan J, Duarte N, Hampton Atkinson J, Grant I, Ellis RJ; CHARTER Group. The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res 2014;218:201-8. [PMID: 24794030 DOI: 10.1016/j.psychres.2014.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
233 Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, Carrero A, García-Álvarez M, Aldámiz-Echevarria T, García-Broncano P, Diez C, Guzmán-Fulgencio M, Fernández-Rodríguez A, Resino S. rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses 2015;31:326-34. [PMID: 25353718 DOI: 10.1089/aid.2014.0195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
234 Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2512. [PMID: 17456578 DOI: 10.1210/jc.2006-2190] [Cited by in Crossref: 1011] [Cited by in F6Publishing: 993] [Article Influence: 67.4] [Reference Citation Analysis]
235 Sutinen J. The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients. PPAR Res 2009;2009:373524. [PMID: 19096512 DOI: 10.1155/2009/373524] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
236 Andrade CS, Jesus RP, Andrade TB, Oliveira NS, Nabity SA, Ribeiro GS. Prevalence and characteristics associated with malnutrition at hospitalization among patients with acquired immunodeficiency syndrome in Brazil. PLoS One 2012;7:e48717. [PMID: 23144941 DOI: 10.1371/journal.pone.0048717] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
237 Masters MC, Krueger KM, Williams JL, Morrison L, Cohn SE. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. Expert Rev Clin Pharmacol 2019;12:1129-43. [PMID: 31774001 DOI: 10.1080/17512433.2019.1698946] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
238 Lai H, Detrick B, Fishman EK, Gerstenblith G, Brinker JA, Hollis BW, Bartlett J, Cofrancesco J Jr, Tong W, Tai H, Chen S, Bhatia S, Lai S. Vitamin D deficiency is associated with the development of subclinical coronary artery disease in African Americans with HIV infection: a preliminary study. J Investig Med 2012;60:801-7. [PMID: 22481166 DOI: 10.2310/JIM.0b013e318250bf99] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
239 De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte Ad, Fontas E, Law MG, Friis-Møller N, Phillips A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008;31:1224-9. [PMID: 18268071 DOI: 10.2337/dc07-2013] [Cited by in Crossref: 340] [Cited by in F6Publishing: 310] [Article Influence: 24.3] [Reference Citation Analysis]
240 Payne BA, Price DA, Chinnery PF. Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infection. AIDS Res Ther 2013;10:27. [PMID: 24252301 DOI: 10.1186/1742-6405-10-27] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
241 Bagchi S, Burrowes SA, Fantry LE, Hossain MB, Tollera GH, Kottilil S, Pauza CD, Miller M, Baumgarten M, Redfield RR. Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population. SAGE Open Med 2017;5:2050312117725644. [PMID: 28839941 DOI: 10.1177/2050312117725644] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
242 Reynolds NR. Cigarette smoking and HIV: more evidence for action. AIDS Educ Prev 2009;21:106-21. [PMID: 19537958 DOI: 10.1521/aeap.2009.21.3_supp.106] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 7.2] [Reference Citation Analysis]
243 Low H, Hoang A, Pushkarsky T, Dubrovsky L, Dewar E, Di Yacovo MS, Mukhamedova N, Cheng L, Downs C, Simon G, Saumoy M, Hill AF, Fitzgerald ML, Nestel P, Dart A, Hoy J, Bukrinsky M, Sviridov D. HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study. PLoS One 2019;14:e0215620. [PMID: 30998801 DOI: 10.1371/journal.pone.0215620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
244 Pontrelli G, Martino AM, Tchidjou HK, Citton R, Mora N, Ravà L, Tozzi AE, Palma P, Muraca M, Franco E, Rossi P, Bernardi S. HIV is associated with thrombophilia and high D-dimer in children and adolescents. AIDS 2010;24:1145-51. [PMID: 20168205 DOI: 10.1097/QAD.0b013e328337b9a0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
245 Vinaixa C, Herreras J, Blanes M, Maupoey J, Berenguer M, Prieto M, Aguilera V. Cardiovascular risk and liver transplantation in HIV patients. Are HIV infected liver transplant recipients at higher risk? Journal of Liver Transplantation 2021;1:100005. [DOI: 10.1016/j.liver.2021.100005] [Reference Citation Analysis]
246 Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, Martin JN, Deeks SG. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009;23:1059-67. [PMID: 19390417 DOI: 10.1097/QAD.0b013e32832b514b] [Cited by in Crossref: 278] [Cited by in F6Publishing: 173] [Article Influence: 21.4] [Reference Citation Analysis]
247 Lambert CT, Sandesara PB, Hirsh B, Shaw LJ, Lewis W, Quyyumi AA, Schinazi RF, Post WS, Sperling L. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review. HIV Med 2016;17:411-24. [PMID: 26611380 DOI: 10.1111/hiv.12346] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
248 Kameczura T, Bryniarski L, Surowiec S, Kocowska M, Kawecka-Jaszcz K, Czarnecka D. Myocardial infarction caused by pharmacological substances - case description and literature review. Postepy Kardiol Interwencyjnej 2013;9:250-5. [PMID: 24570727 DOI: 10.5114/pwki.2013.37504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Currier JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Tebas P, Li Y, Hodis HN. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007;21:1137-45. [PMID: 17502724 DOI: 10.1097/QAD.0b013e32811ebf79] [Cited by in Crossref: 102] [Cited by in F6Publishing: 53] [Article Influence: 6.8] [Reference Citation Analysis]
250 McCormick CL, Francis AM, Iliffe K, Webb H, Douch CJ, Pakianathan M, Macallan DC. Increasing Obesity in Treated Female HIV Patients from Sub-Saharan Africa: Potential Causes and Possible Targets for Intervention. Front Immunol 2014;5:507. [PMID: 25431572 DOI: 10.3389/fimmu.2014.00507] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
251 Mahungu TW, Rodger AJ, Johnson MA. HIV as a chronic disease. Clin Med (Lond) 2009;9:125-8. [PMID: 19435115 DOI: 10.7861/clinmedicine.9-2-125] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
252 Lin X, Ammosova T, Kumari N, Nekhai S. Protein Phosphatase-1 -targeted Small Molecules, Iron Chelators and Curcumin Analogs as HIV-1 Antivirals. Curr Pharm Des 2017;23:4122-32. [PMID: 28677499 DOI: 10.2174/1381612823666170704123620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
253 Wongcharoen W, Khienprasit K, Phrommintikul A, Sukonthasarn A, Chattipakorn N. Heart rate variability and heart rate turbulence in HIV-infected patients receiving combination antiretroviral therapy. Ann Noninvasive Electrocardiol 2013;18:450-6. [PMID: 24047489 DOI: 10.1111/anec.12064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
254 Tungsiripat M, El-Bejjani D, Rizk N, Dogra V, O'Riordan MA, Ross AC, Hileman C, Storer N, Harrill D, McComsey GA. Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses 2011;27:295-302. [PMID: 20969457 DOI: 10.1089/aid.2010.0187] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
255 Kumar S, Samaras K. The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endocrinol (Lausanne) 2018;9:705. [PMID: 30542325 DOI: 10.3389/fendo.2018.00705] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
256 Tsiodras S, Mantzoros C. Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications. Am J Infect Dis 2006;2:141-52. [PMID: 17183414 DOI: 10.3844/ajidsp.2006.141.152] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
257 Marzocchetti A, Schwarz J, Di Giambenedetto S, Colafigli M, Bracciale L, Fabbiani M, Fantoni M, Trecarichi E, Cauda R, De Luca A. The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. AIDS Res Hum Retroviruses 2011;27:1299-309. [PMID: 21595566 DOI: 10.1089/aid.2010.0172] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
258 Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte Ad, Pradier C, Thiebaut R, Law M, Rickenbach M, De Wit S, Lundgren JD, Friis-Møller N. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2009;32:474-80. [PMID: 19056612 DOI: 10.2337/dc08-1394] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
259 Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 2005;19:357-70. [PMID: 15750389 DOI: 10.1097/01.aids.0000161765.75663.27] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
260 Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojic EM. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 2008;47:459-466. [PMID: 17971707 DOI: 10.1097/qai.0b013e31815bace2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
261 Patel S, Weiss E, Chhabra R, Ryniker L, Adsuar R, Carness J, Kahalas W, Delamarter C, Feldman IS, Delorenzo JP, Tanner E, Rapkin B. The Events in Care Screening Questionnaire (ECSQ): a new tool to identify needs and concerns of people with HIV/AIDS. AIDS Patient Care STDS 2008;22:381-93. [PMID: 18366327 DOI: 10.1089/apc.2007.0105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
262 Levy AR, McCandless L, Harrigan PR, Hogg RS, Bondy G, Iloeje UH, Mukherjee J, Montaner JS. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis 2005;4:4. [PMID: 15705191 DOI: 10.1186/1476-511X-4-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
263 McManus KA, Pinkerton R, Dillingham R. Effects of recent Virginia AIDS Drug Assistance Program policy changes on diabetes and hyperlipidemia control in people living with HIV. SAGE Open Med 2014;2:2050312114532809. [PMID: 25544885 DOI: 10.1177/2050312114532809] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
264 Buchacz K, Armon C, Palella FJ Jr, Novak RM, Fuhrer J, Tedaldi E, Ward D, Mayer C, Battalora L, Carlson K, Purinton S, Durham M, Li J; HIV Outpatient Study (HOPS) Investigators . The HIV Outpatient Study-25 Years of HIV Patient Care and Epidemiologic Research. Open Forum Infect Dis 2020;7:ofaa123. [PMID: 32455145 DOI: 10.1093/ofid/ofaa123] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
265 Looby SE. Menopause-associated metabolic manifestations and symptomatology in HIV infection: a brief review with research implications. J Assoc Nurses AIDS Care 2012;23:195-203. [PMID: 21924646 DOI: 10.1016/j.jana.2011.06.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
266 Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis 2013;13:471. [PMID: 24106926 DOI: 10.1186/1471-2334-13-471] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.8] [Reference Citation Analysis]
267 Antonioiribarren J, Labarga P, Rubio R, Berenguer J, Miró J, Antela A, González J, Moreno S, Arrizabalaga J, Chamorro L, Clotet B, Gatell JM, López-aldeguer J, Martínez E, Polo R, Tuset M, Viciana P, Miguel Santamaría J, María Kindelán J, Ribera E, Segura F. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004). Enfermedades Infecciosas y Microbiología Clínica 2004;22:564-642. [DOI: 10.1016/s0213-005x(04)73163-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
268 Jerebtsova M, Ahmad A, Niu X, Rutagarama O, Nekhai S. HIV-1 Transcription Inhibitor 1E7-03 Restores LPS-Induced Alteration of Lung Leukocytes' Infiltration Dynamics and Resolves Inflammation in HIV Transgenic Mice. Viruses 2020;12:E204. [PMID: 32059509 DOI: 10.3390/v12020204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
269 Ryom L, Lundgren JD, De Wit S, Kovari H, Reiss P, Law M, El-Sadr W, Monforte AD, Mocroft A, Smith C, Fontas E, Dabis F, Phillips A, Sabin C; D:A:D Study Group. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS 2016;30:1731-43. [PMID: 26752282 DOI: 10.1097/QAD.0000000000001018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
270 Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, Moore RD, Chaisson RE, Grant AD, Churchyard GJ. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 2011;58:269-76. [PMID: 21876447 DOI: 10.1097/QAI.0b013e31823219d1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
271 Benard A, Bonnet F, Tessier JF, Fossoux H, Dupon M, Mercie P, Ragnaud JM, Viallard JF, Dabis F, Chene G; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS 2007;21:458-68. [PMID: 17651027 DOI: 10.1089/apc.2006.0142] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 6.6] [Reference Citation Analysis]
272 Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med 2005;353:1702-10. [PMID: 16236741 DOI: 10.1056/NEJMcp051203] [Cited by in Crossref: 54] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
273 Bongiovanni M, Bini T, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Biasi P, Adorni F, Monforte AD. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. AIDS Res Hum Retroviruses 2006;22:132-8. [PMID: 16478394 DOI: 10.1089/aid.2006.22.132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
274 Vreeman RC, Scanlon ML, McHenry MS, Nyandiko WM. The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children. J Int AIDS Soc 2015;18:20258. [PMID: 26639114 DOI: 10.7448/IAS.18.7.20258] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
275 Korem M, Wallach T, Bursztyn M, Maayan S, Olshtain-Pops K. High Prevalence of Hypertension in Ethiopian and Non-Ethiopian HIV-Infected Adults. Int J Hypertens 2018;2018:8637101. [PMID: 29623220 DOI: 10.1155/2018/8637101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
276 Schneider CL, Mohajeri-Moghaddam S, Mbewe EG, Kabundula PP, Dean O, Buda A, Potchen MJ, Mwanza-Kabaghe S, Saylor D, Adams HR, Birbeck GL, Bearden DR. Cerebrovascular Disease in Children Perinatally Infected With Human Immunodeficiency Virus in Zambia. Pediatr Neurol 2020;112:14-21. [PMID: 32871411 DOI: 10.1016/j.pediatrneurol.2020.08.003] [Reference Citation Analysis]
277 van den Dries LW, Gruters RA, Hövels-van der Borden SB, Kruip MJ, de Maat MP, van Gorp EC, van der Ende ME. von Willebrand Factor is elevated in HIV patients with a history of thrombosis. Front Microbiol 2015;6:180. [PMID: 25814984 DOI: 10.3389/fmicb.2015.00180] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
278 Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, Saag MS. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011;25:691-700. [PMID: 21160411 DOI: 10.1097/QAD.0b013e3283437f77] [Cited by in Crossref: 82] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
279 Radford M, Parks DC, Ferrante S, Punekar Y. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. AIDS 2019;33:1739-49. [PMID: 31180906 DOI: 10.1097/QAD.0000000000002285] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
280 Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008;300:509-19. [PMID: 18677023 DOI: 10.1001/jama.300.5.509] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 4.7] [Reference Citation Analysis]
281 Crane HM, Heckbert SR, Drozd DR, Budoff MJ, Delaney JA, Rodriguez C, Paramsothy P, Lober WB, Burkholder G, Willig JH, Mugavero MJ, Mathews WC, Crane PK, Moore RD, Napravnik S, Eron JJ, Hunt P, Geng E, Hsue P, Barnes GS, McReynolds J, Peter I, Grunfeld C, Saag MS, Kitahata MM; Centers for AIDS Research Network of Integrated Clinical Systems Cohort Investigators. Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. Am J Epidemiol 2014;179:996-1005. [PMID: 24618065 DOI: 10.1093/aje/kwu010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
282 Morris A, George MP, Crothers K, Huang L, Lucht L, Kessinger C, Kleerup EC; Lung HIV Study. HIV and chronic obstructive pulmonary disease: is it worse and why? Proc Am Thorac Soc 2011;8:320-5. [PMID: 21653535 DOI: 10.1513/pats.201006-045WR] [Cited by in Crossref: 72] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
283 Langkilde A, Petersen J, Klausen HH, Henriksen JH, Eugen-Olsen J, Andersen O. Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study. PLoS One 2012;7:e51698. [PMID: 23251607 DOI: 10.1371/journal.pone.0051698] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
284 Denue BA, Alkali MB, Abjah AU, Kida IM, Ajayi B, Fate BZ. Changes in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen. Infect Dis (Auckl) 2013;6:7-14. [PMID: 24847172 DOI: 10.4137/IDRT.S10044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
285 Walker JA, Sulciner ML, Nowicki KD, Miller AD, Burdo TH, Williams KC. Elevated numbers of CD163+ macrophages in hearts of simian immunodeficiency virus-infected monkeys correlate with cardiac pathology and fibrosis. AIDS Res Hum Retroviruses 2014;30:685-94. [PMID: 24524407 DOI: 10.1089/AID.2013.0268] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
286 Zhang J, O'Leary A, Jemmott JB 3rd, Icard LD, Rutledge SE. Syndemic conditions predict lower levels of physical activity among African American men who have sex with men: A prospective survey study. PLoS One 2019;14:e0213439. [PMID: 30865694 DOI: 10.1371/journal.pone.0213439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
287 Kann G, Owasil J, Kuczka K, Haberl A, Wolf T, Khaykin P, Harder S, Stephan C, von Hentig N. Evaluation of Platelet Activation by HIV Protease Inhibitors - The HIV-PLA II Study. HIV AIDS (Auckl) 2021;13:789-800. [PMID: 34393518 DOI: 10.2147/HIV.S262282] [Reference Citation Analysis]
288 De Pablo C, Orden S, Apostolova N, Blanquer A, Esplugues JV, Alvarez A. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. AIDS 2010;24:1259-66. [PMID: 20453628 DOI: 10.1097/QAD.0b013e32833a2b02] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
289 Kebodeaux CD, Wilson AG, Smith DL, Vouri SM. A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV. HIV AIDS (Auckl) 2013;5:263-74. [PMID: 24068878 DOI: 10.2147/HIV.S36311] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
290 Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, Delpech V, Phillips AN. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012;26:335-43. [PMID: 22089374 DOI: 10.1097/QAD.0b013e32834dcec9] [Cited by in Crossref: 293] [Cited by in F6Publishing: 176] [Article Influence: 29.3] [Reference Citation Analysis]
291 Duan M, Yao H, Hu G, Chen X, Lund AK, Buch S. HIV Tat induces expression of ICAM-1 in HUVECs: implications for miR-221/-222 in HIV-associated cardiomyopathy. PLoS One. 2013;8:e60170. [PMID: 23555914 DOI: 10.1371/journal.pone.0060170] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
292 Kietsiriroje N, Leelawattana R. Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study. BMC Res Notes 2015;8:294. [PMID: 26148680 DOI: 10.1186/s13104-015-1225-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
293 Nass R, Thorner MO. Does low-dose growth hormone therapy improve the body composition of patients infected with HIV? Nat Clin Pract Endocrinol Metab 2009;5:142-3. [PMID: 19153561 DOI: 10.1038/ncpendmet1064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
294 Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005;150:933. [PMID: 16290967 DOI: 10.1016/j.ahj.2005.06.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 3.7] [Reference Citation Analysis]
295 Vinikoor MJ, Napravnik S, Floris-Moore M, Wilson S, Huang DY, Eron JJ. Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. AIDS Res Hum Retroviruses 2013;29:1068-74. [PMID: 23565888 DOI: 10.1089/aid.2012.0334] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
296 Zanni MV, Grinspoon SK. HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rep 2012;9:200-5. [PMID: 22638983 DOI: 10.1007/s11904-012-0123-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
297 Metkus TS Jr, Brown TT, Post WS. Cardiovascular disease associated with the human immunodeficiency virus: an update. Curr Treat Options Cardiovasc Med 2014;16:346. [PMID: 25193559 DOI: 10.1007/s11936-014-0346-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
298 Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M, Niero F, Biasin M, Bonfanti P, Ricci ED, Trabattoni D, Clerici M. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS 2013;27:381-9. [PMID: 23079800 DOI: 10.1097/QAD.0b013e32835abcc9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
299 Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep. 2012;9:206-217. [PMID: 22752405 DOI: 10.1007/s11904-012-0124-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 6.3] [Reference Citation Analysis]
300 Zheng X, Gong L, Xue W, Zeng S, Xu Y, Zhang Y, Hu X. Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis. AIDS Res Ther 2019;16:37. [PMID: 31747972 DOI: 10.1186/s12981-019-0253-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
301 Polanka BM, Gupta SK, So-Armah KA, Freiberg MS, Zapolski TCB, Hirsh AT, Stewart JC. Examining Depression as a Risk Factor for Cardiovascular Disease in People with HIV: A Systematic Review. Ann Behav Med 2022:kaab119. [PMID: 35481701 DOI: 10.1093/abm/kaab119] [Reference Citation Analysis]
302 Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007;44:726-34. [PMID: 17278068 DOI: 10.1086/511679] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 8.8] [Reference Citation Analysis]
303 Delaney JA, Scherzer R, Biggs ML, Shliplak MG, Polak JF, Currier JS, Kronmal RA, Wanke C, Bacchetti P, O'leary D, Tien PC, Grunfeld C. Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS 2010;24:2201-9. [PMID: 20671544 DOI: 10.1097/QAD.0b013e32833d2132] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
304 Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M; TAILoR Study Group. TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clin Infect Dis 2020;70:2062-72. [PMID: 31425580 DOI: 10.1093/cid/ciz589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
305 Van den Hof M, Klein Haneveld MJ, Blokhuis C, Scherpbier HJ, Jansen HPG, Kootstra NA, Dallinga-Thie GM, Van Deventer SJH, Tsimikas S, Pajkrt D; NOVICE study group . Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared With Healthy Ethnicity-Matched Controls. Open Forum Infect Dis 2019;6:ofz301. [PMID: 31660394 DOI: 10.1093/ofid/ofz301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
306 Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 2009;69:1107-40. [PMID: 19496633 DOI: 10.2165/00003495-200969080-00009] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
307 Kenny J, Mulenga V, Hoskins S, Scholten F, Gibb DM. The needs for HIV treatment and care of children, adolescents, pregnant women and older people in low-income and middle-income countries. AIDS 2012;26 Suppl 2:S105-16. [PMID: 23303433 DOI: 10.1097/QAD.0b013e32835bddfc] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
308 Crane HM, Paramsothy P, Drozd DR, Nance RM, Delaney JA, Heckbert SR, Budoff MJ, Burkholder GA, Willig JH, Mugavero MJ, Mathews WC, Crane PK, Moore RD, Eron JJ, Napravnik S, Hunt PW, Geng E, Hsue P, Rodriguez C, Peter I, Barnes GS, McReynolds J, Lober WB, Crothers K, Feinstein MJ, Grunfeld C, Saag MS, Kitahata MM; Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort. Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States. JAMA Cardiol 2017;2:260-7. [PMID: 28052152 DOI: 10.1001/jamacardio.2016.5139] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
309 Whiteside YO, Selik R, An Q, Huang T, Karch D, Hernandez AL, Hall HI. Comparison of Rates of Death Having any Death-Certificate Mention of Heart, Kidney, or Liver Disease Among Persons Diagnosed with HIV Infection with those in the General US Population, 2009-2011. Open AIDS J 2015;9:14-22. [PMID: 25767634 DOI: 10.2174/1874613601509010014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
310 Ammirati E, Moroni F, Magnoni M, Camici PG. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol 2015;179:173-87. [PMID: 25352024 DOI: 10.1111/cei.12477] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 11.4] [Reference Citation Analysis]
311 García-Benayas T, Blanco F, Alcolea A, Cruz JJ, González-Lahoz J, Soriano V. Short communication: benefits in the lipid profile after substitution of abacavir for Stavudine: a 48-week prospective study. AIDS Res Hum Retroviruses 2004;20:1289-92. [PMID: 15650420 DOI: 10.1089/aid.2004.20.1289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
312 Hadigan C, Liebau J, Torriani M, Andersen R, Grinspoon S. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab. 2006;91:4438-4444. [PMID: 16940448 DOI: 10.1210/jc.2006-1174] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
313 Polsky S, Floris-Moore M, Schoenbaum EE, Klein RS, Arnsten JH, Howard AA. Incident hyperglycaemia among older adults with or at-risk for HIV infection. Antivir Ther 2011;16:181-8. [PMID: 21447867 DOI: 10.3851/IMP1711] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
314 Eckard AR, Tangpricha V, Seydafkan S, O'Riordan MA, Storer N, Labbato D, McComsey GA. The relationship between vitamin D status and HIV-related complications in HIV-infected children and young adults. Pediatr Infect Dis J 2013;32:1224-9. [PMID: 23360833 DOI: 10.1097/INF.0b013e318286c793] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
315 Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, So-Armah KA, Vasan RS, Oursler KA, Gottdiener J, Gottlieb S, Leaf D, Rodriguez-Barradas M, Tracy RP, Gibert CL, Rimland D, Bedimo RJ, Brown ST, Goetz MB, Warner A, Crothers K, Tindle HA, Alcorn C, Bachmann JM, Justice AC, Butt AA. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study. JAMA Cardiol 2017;2:536-46. [PMID: 28384660 DOI: 10.1001/jamacardio.2017.0264] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 39.0] [Reference Citation Analysis]
316 Lake JE, Currier JS. Switching antiretroviral therapy to minimize metabolic complications. HIV Ther 2010;4:693-711. [PMID: 22171239 DOI: 10.2217/hiv.10.47] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
317 van Genderen JG, Van den Hof M, de Boer CG, Jansen HPG, van Deventer SJH, Tsimikas S, Witztum JL, Kastelein JJP, Pajkrt D. Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents. Viruses 2021;13:2067. [PMID: 34696496 DOI: 10.3390/v13102067] [Reference Citation Analysis]
318 McDonald CL, Kaltman JR. Cardiovascular disease in adult and pediatric HIV/AIDS. J Am Coll Cardiol 2009;54:1185-8. [PMID: 19761941 DOI: 10.1016/j.jacc.2009.05.055] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
319 Gutierrez AD, Balasubramanyam A. Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine. 2012;41:1-10. [PMID: 22134974 DOI: 10.1007/s12020-011-9565-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
320 Freitas P, Carvalho D, Souto S, Santos AC, Xerinda S, Marques R, Martinez E, Sarmento A, Medina JL. Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients. BMC Infect Dis 2011;11:246. [PMID: 21933422 DOI: 10.1186/1471-2334-11-246] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
321 Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, Gonin R, Korelitz J, Douglas SD. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One. 2011;6:e24180. [PMID: 21931661 DOI: 10.1371/journal.pone.0024180] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
322 Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M; Antiretroviral Therapy Cohort Collaboration (ART-CC). Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009;48:1138-51. [PMID: 19275498 DOI: 10.1086/597468] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 5.5] [Reference Citation Analysis]
323 Luo L, Zhang L, Tao M, Qiu Z, Xie J, Han Y, Li M, Li T. Adiponectin and leptin levels in Chinese patients with HIV-related lipodystrophy: a 30-month prospective study. AIDS Res Hum Retroviruses 2009;25:1265-72. [PMID: 20001516 DOI: 10.1089/aid.2009.0072] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
324 Molino Cde G, Carnevale RC, Rodrigues AT, Visacri MB, Moriel P, Mazzola PG. Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection. Ther Clin Risk Manag 2014;10:631-9. [PMID: 25120369 DOI: 10.2147/TCRM.S61821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
325 Esplugues JV, De Pablo C, Collado-Díaz V, Hernández C, Orden S, Álvarez Á. Interference with purinergic signalling: an explanation for the cardiovascular effect of abacavir? AIDS 2016;30:1341-51. [PMID: 26990628 DOI: 10.1097/QAD.0000000000001088] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
326 Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014;10:e1004071. [PMID: 24722454 DOI: 10.1371/journal.ppat.1004071] [Cited by in Crossref: 191] [Cited by in F6Publishing: 185] [Article Influence: 23.9] [Reference Citation Analysis]
327 Carr A, Ory D. Does HIV cause cardiovascular disease? PLoS Med 2006;3:e496. [PMID: 17132070 DOI: 10.1371/journal.pmed.0030496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
328 Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 2008;10:61-70. [PMID: 18366987 DOI: 10.1007/s11883-008-0010-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
329 De Lorenzo F, Boffito M, Collot-Teixeira S, Gazzard B, McGregor JL, Shotliff K, Xiao H. Prevention of atherosclerosis in patients living with HIV. Vasc Health Risk Manag 2009;5:287-300. [PMID: 19436663 DOI: 10.2147/vhrm.s5206] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
330 Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med 2008;148:178-85. [PMID: 18252681 DOI: 10.7326/0003-4819-148-3-200802050-00004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
331 Bares SH, Smeaton LM, Xu A, Godfrey C, McComsey GA. HIV-Infected Women Gain More Weight than HIV-Infected Men Following the Initiation of Antiretroviral Therapy. J Womens Health (Larchmt) 2018;27:1162-9. [PMID: 29608129 DOI: 10.1089/jwh.2017.6717] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
332 Gupta SK, Parker RA, Robbins GK, Dubé MP. The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: results from a randomized trial. Nephrol Dial Transplant 2005;20:2237-42. [PMID: 16105869 DOI: 10.1093/ndt/gfi053] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
333 Cade WT, Overton ET, Mondy K, de las Fuentes L, Davila-Roman VG, Waggoner AD, Reeds DN, Lassa-Claxton S, Krauss MJ, Peterson LR, Yarasheski KE. Relationships among HIV infection, metabolic risk factors, and left ventricular structure and function. AIDS Res Hum Retroviruses 2013;29:1151-60. [PMID: 23574474 DOI: 10.1089/AID.2012.0254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
334 Hileman CO, Kinley B, Scharen-Guivel V, Melbourne K, Szwarcberg J, Robinson J, Lederman MM, Mccomsey GA. Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals. J Infect Dis 2015;212:345-54. [PMID: 25583168 DOI: 10.1093/infdis/jiv004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
335 Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, Heymsfield S, Tien P, Bacchetti P, Scherzer R, Grunfeld C. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr. 2008;48:142-148. [PMID: 18344877 DOI: 10.1097/qai.0b013e3181685727] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
336 Vogel M, Friedrich O, Lüchters G, Holleczek B, Wasmuth JC, Anadol E, Schwarze-Zander C, Nattermann J, Oldenburg J, Sauerbruch T, Rockstroh JK, Spengler U. Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence. Eur J Med Res 2011;16:101-7. [PMID: 21486722 DOI: 10.1186/2047-783x-16-3-101] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
337 Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM; A5170 Study Team. Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. J Acquir Immune Defic Syndr 2008;49:377-83. [PMID: 18931631 DOI: 10.1097/QAI.0b013e31818cde21] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
338 Mathabire Rücker SC, Tayea A, Bitilinyu-Bangoh J, Bermúdez-Aza EH, Salumu L, Quiles IA, Szumilin E, Chirwa Z, Rick F, Maman D. High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi. AIDS 2018;32:253-60. [PMID: 29135581 DOI: 10.1097/QAD.0000000000001700] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
339 Gutierrez J, Ortiz G. HIV/AIDS patients with HIV vasculopathy and VZV vasculitis: a case series. Clin Neuroradiol 2011;21:145-51. [PMID: 21773670 DOI: 10.1007/s00062-011-0087-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
340 Delabays B, Cavassini M, Damas J, Beuret H, Calmy A, Hasse B, Bucher HC, Frischknecht M, Müller O, Méan M, Vollenweider P, Marques-Vidal P, Vaucher J. Cardiovascular risk assessment in people living with HIV compared to the general population. Eur J Prev Cardiol 2021:zwab201. [PMID: 34893801 DOI: 10.1093/eurjpc/zwab201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Boyd MA, Hill AM. Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. Pharmacoeconomics 2010;28 Suppl 1:17-34. [PMID: 21182341 DOI: 10.2165/11587420-000000000-00000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
342 Nery MW, Martelli CM, Silveira EA, de Sousa CA, Falco Mde O, de Castro Ade C, Esper JT, Souza LC, Turchi MD. Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. ScientificWorldJournal 2013;2013:969281. [PMID: 24228022 DOI: 10.1155/2013/969281] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
343 Pefura Yone EW, Kengne AP, Ashuntantang G, Betyoumin AF, Ngogang J. Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study. BMJ Open 2012;2:e001317. [PMID: 22874631 DOI: 10.1136/bmjopen-2012-001317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
344 Carballo D, Delhumeau C, Carballo S, Bähler C, Radovanovic D, Hirschel B, Clerc O, Bernasconi E, Fasel D, Schmid P, Cusini A, Fehr J, Erne P, Keller PF, Ledergerber B, Calmy A; Swiss HIV Cohort Study and AMIS registry. Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. AIDS Res Ther 2015;12:4. [PMID: 25705241 DOI: 10.1186/s12981-015-0045-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
345 O'Dwyer EJ, Bhamra-Ariza P, Rao S, Emmanuel S, Carr A, Holloway CJ. Lower coronary plaque burden in patients with HIV presenting with acute coronary syndrome. Open Heart 2016;3:e000511. [PMID: 28123757 DOI: 10.1136/openhrt-2016-000511] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
346 Lange DC, Glidden D, Secemsky EA, Ordovas K, Deeks SG, Martin JN, Bolger AF, Hsue PY. Mitral Annular and Coronary Artery Calcification Are Associated with Mortality in HIV-Infected Individuals. PLoS One 2015;10:e0130592. [PMID: 26132465 DOI: 10.1371/journal.pone.0130592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
347 Yuyun MF, Sliwa K, Kengne AP, Mocumbi AO, Bukhman G. Cardiovascular Diseases in Sub-Saharan Africa Compared to High-Income Countries: An Epidemiological Perspective. Glob Heart 2020;15:15. [PMID: 32489788 DOI: 10.5334/gh.403] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
348 Bravo CA, Hua S, Deik A, Lazar J, Hanna DB, Scott J, Chai JC, Kaplan RC, Anastos K, Robles OA, Clish CB, Kizer JR, Qi Q. Metabolomic Profiling of Left Ventricular Diastolic Dysfunction in Women With or at Risk for HIV Infection: The Women's Interagency HIV Study. J Am Heart Assoc 2020;9:e013522. [PMID: 32063116 DOI: 10.1161/JAHA.119.013522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
349 Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS 2005;19:641-52. [PMID: 15821390 DOI: 10.1097/01.aids.0000166087.08822.bc] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
350 Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation 2009;119:805-11. [PMID: 19188509 DOI: 10.1161/CIRCULATIONAHA.108.790857] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
351 Nolan D, Reiss P, Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 2005;4:201-18. [PMID: 15794714 DOI: 10.1517/14740338.4.2.201] [Reference Citation Analysis]
352 Sears S, Buendia JR, Odem S, Qobadi M, Wortley P, Mgbere O, Sanders J, Spencer EC, Barnes A. Metabolic Syndrome Among People Living with HIV Receiving Medical Care in Southern United States: Prevalence and Risk Factors. AIDS Behav 2019;23:2916-25. [PMID: 30929149 DOI: 10.1007/s10461-019-02487-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
353 Wiener M, Lo Y, Klein RS. Abnormal thyroid function in older men with or at risk for HIV infection. HIV Med 2008;9:544-9. [PMID: 18554308 DOI: 10.1111/j.1468-1293.2008.00601.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
354 Braconnier P, Delforge M, Garjau M, Wissing KM, De Wit S. Hyponatremia is a marker of disease severity in HIV-infected patients: a retrospective cohort study. BMC Infect Dis 2017;17:98. [PMID: 28122494 DOI: 10.1186/s12879-017-2191-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
355 Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, Schouten J, Mickelberg K, Li Y, Hodis HN; AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005;19:927-33. [PMID: 15905673 DOI: 10.1097/01.aids.0000171406.53737.f9] [Cited by in Crossref: 127] [Cited by in F6Publishing: 118] [Article Influence: 7.5] [Reference Citation Analysis]
356 Grandi AM, Nicolini E, Rizzi L, Caputo S, Annoni F, Cremona AM, Marchesi C, Guasti L, Maresca AM, Grossi P. Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy. J Int AIDS Soc. 2014;17:19004. [PMID: 25148829 DOI: 10.7448/ias.17.1.19004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
357 Lake JE, Wohl D, Scherzer R, Grunfeld C, Tien PC, Sidney S, Currier JS. Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care 2011;23:929-38. [PMID: 21767228 DOI: 10.1080/09540121.2010.543885] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
358 Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ; ACTG 5087 Study Team. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005;21:757-67. [PMID: 16218799 DOI: 10.1089/aid.2005.21.757] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 5.1] [Reference Citation Analysis]
359 Severino P, D'Amato A, Pucci M, Infusino F, Adamo F, Birtolo LI, Netti L, Montefusco G, Chimenti C, Lavalle C, Maestrini V, Mancone M, Chilian WM, Fedele F. Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. Int J Mol Sci 2020;21:E8118. [PMID: 33143256 DOI: 10.3390/ijms21218118] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
360 Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases 2017; 5(2): 40-45 [PMID: 28255546 DOI: 10.12998/wjcc.v5.i2.40] [Reference Citation Analysis]
361 Castillo-Mancilla JR, Cavassini M, Schneider MP, Furrer H, Calmy A, Battegay M, Scanferla G, Bernasconi E, Günthard HF, Glass TR; Swiss HIV Cohort Study . Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. Open Forum Infect Dis 2021;8:ofab032. [PMID: 33604408 DOI: 10.1093/ofid/ofab032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
362 Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, Levitt NS, Crowther NJ, Nyirenda M, Njelekela M. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol. 2013;42:1754-1771. [PMID: 24415610 DOI: 10.1093/ije/dyt198] [Cited by in Crossref: 109] [Cited by in F6Publishing: 114] [Article Influence: 13.6] [Reference Citation Analysis]
363 Stein SA, Mc Nurlan M, Phillips BT, Messina C, Mynarcik D, Gelato M. Chromium Therapy for Insulin Resistance Associated with HIV-Disease. J AIDS Clin Res 2013;4:239. [PMID: 25346863 DOI: 10.4172/2155-6113.1000239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
364 Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag 2015;11:35-48. [PMID: 25609975 DOI: 10.2147/VHRM.S65885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
365 Kohli R, Klein RS, Schoenbaum EE, Anastos K, Minkoff H, Sacks HS. Aging and HIV infection. J Urban Health 2006;83:31-42. [PMID: 16736353 DOI: 10.1007/s11524-005-9005-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
366 Armstrong C, Liu E, Okuma J, Spiegelman D, Guerino C, Njelekela M, Grinspoon S, Fawzi W, Hawkins C. Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2011;57:141-5. [PMID: 21436713 DOI: 10.1097/QAI.0b013e318219a3d1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
367 Lai H, Gerstenblith G, Fishman EK, Brinker J, Kickler T, Tong W, Bhatia S, Hong T, Chen S, Li J, Detrick B, Lai S. Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis 2012;54:1747-55. [PMID: 22423137 DOI: 10.1093/cid/cis306] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
368 Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Sørensen HT, Gerstoft J. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011;6:e22698. [PMID: 21799935 DOI: 10.1371/journal.pone.0022698] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 9.2] [Reference Citation Analysis]
369 Babiker AG, Emery S, Fätkenheuer G, Gordin FM, Grund B, Lundgren JD, Neaton JD, Pett SL, Phillips A, Touloumi G, Vjechaj MJ; INSIGHT START Study Group. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013;10:S5-S36. [PMID: 22547421 DOI: 10.1177/1740774512440342] [Cited by in Crossref: 74] [Cited by in F6Publishing: 79] [Article Influence: 7.4] [Reference Citation Analysis]
370 Spieker LE, Karadag B, Binggeli C, Corti R. Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection. Heart Vessels 2005;20:171-4. [PMID: 16025368 DOI: 10.1007/s00380-004-0790-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
371 Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis 2010;17:72-82. [PMID: 20005491 DOI: 10.1053/j.ackd.2009.07.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
372 Wright EJ, Nunn M, Joseph J, Robertson K, Lal L, Brew BJ. NeuroAIDS in the Asia Pacific Region. J Neurovirol 2008;14:465-73. [PMID: 19031289 DOI: 10.1080/13550280802235932] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
373 . 8.0 Antiretroviral therapy in specific populations: BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2014;15:58-81. [DOI: 10.1111/hiv.12119_9] [Reference Citation Analysis]
374 Oramasionwu CU, Hunter JM, Brown CM, Morse GD, Lawson KA, Koeller JM, Frei CR. Cardiovascular Disease in Blacks with HIV/AIDS in the United States: A Systematic Review of the Literature. Open AIDS J 2012;6:29-35. [PMID: 22563364 DOI: 10.2174/1874613601206010029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
375 Monteiro P, Miranda-Filho DB, Bandeira F, Lacerda HR, Chaves H, Albuquerque MF, Montarroyos UR, Ximenes RA. Is arterial stiffness in HIV-infected individuals associated with HIV-related factors? Braz J Med Biol Res 2012;45:818-26. [PMID: 22782555 DOI: 10.1590/s0100-879x2012007500116] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
376 Chen R, Scherzer R, Hsue PY, Jotwani V, Estrella MM, Horberg MA, Grunfeld C, Shlipak MG. Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. J Am Heart Assoc 2017;6:e005387. [PMID: 28438737 DOI: 10.1161/JAHA.116.005387] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
377 Fichtenbaum CJ. Does antiretroviral therapy increase or decrease the risk of cardiovascular disease? Curr HIV/AIDS Rep 2010;7:92-8. [PMID: 20425563 DOI: 10.1007/s11904-010-0045-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
378 Glesby MJ. Coronary heart disease in HIV-infected patients. Curr HIV/AIDS Rep 2005;2:68-73. [PMID: 16091251 DOI: 10.1007/s11904-005-0021-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
379 Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis 2012;206:534-42. [PMID: 22740718 DOI: 10.1093/infdis/jis376] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]
380 Patel AA, Budoff MJ. Coronary artery disease in patients with HIV infection. Am J Cardiovasc Drugs 2015;15:81-7. [PMID: 25672641 DOI: 10.1007/s40256-015-0105-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
381 Evans SR, Fichtenbaum CJ, Aberg JA; A5087 Study Team. Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087. HIV Clin Trials 2007;8:45-52. [PMID: 17434848 DOI: 10.1310/hct0801-45] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
382 Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses 2013;29:435-40. [PMID: 23072344 DOI: 10.1089/aid.2012.0234] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 8.6] [Reference Citation Analysis]
383 Sacilotto LB, Papini SJ, Mendes AL, Gatto M, Pereira PCM, Corrente JE, da Silva JF. Relationship Between Lipodystrophy, Body Composition, Metabolic Profile, and Serum Levels of Adipocytokines. Front Nutr 2021;8:750721. [PMID: 34957175 DOI: 10.3389/fnut.2021.750721] [Reference Citation Analysis]
384 Lu G, Thomas-Geevarghese A, Anuurad E, Raghavan S, Minolfo R, Ormsby B, Karmally W, El-Sadr WM, Albu J, Berglund L. Relationship of postprandial nonesterified fatty acids, adipokines, and insulin across gender in human immunodeficiency virus-positive patients undergoing highly active antiretroviral therapy. Metab Syndr Relat Disord 2009;7:199-204. [PMID: 19320559 DOI: 10.1089/met.2008.0066] [Reference Citation Analysis]
385 Mulligan K, Harris DR, Monte D, Stoszek S, Emmanuel P, Hardin DS, Kapogiannis BG, Worrell C, Meyer WA 3rd, Sleasman J, Wilson CM, Aldrovandi GM; Adolescent Trials Network 021 Protocol Team. Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. Clin Infect Dis 2010;50:106-14. [PMID: 19947855 DOI: 10.1086/648728] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
386 Crum-Cianflone N, Roediger MP, Eberly L, Headd M, Marconi V, Ganesan A, Weintrob A, Barthel RV, Fraser S, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One 2010;5:e10106. [PMID: 20419086 DOI: 10.1371/journal.pone.0010106] [Cited by in Crossref: 137] [Cited by in F6Publishing: 132] [Article Influence: 11.4] [Reference Citation Analysis]
387 Wohl DA, Waters D, Simpson RJ, Richard S, Schnell A, Napravnik S, Keys J, Eron JJ, Hsue P. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2008;47:1105-1108. [PMID: 18781882 DOI: 10.1086/592116] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
388 Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, Martinelli CV, De Socio GV, Squillace N, Rusconi S, Bonfanti P, Di Biagio A; CISAI Study Group . Weight Gain: A Possible Side Effect of All Antiretrovirals. Open Forum Infect Dis 2017;4:ofx239. [PMID: 29255735 DOI: 10.1093/ofid/ofx239] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
389 Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, Harrill D, Tungsiripat M, Adell J, McComsey GA. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009;49:1119-27. [PMID: 19712036 DOI: 10.1086/605578] [Cited by in Crossref: 165] [Cited by in F6Publishing: 169] [Article Influence: 12.7] [Reference Citation Analysis]
390 Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, Masur H, Meigs JB, Mulligan K, Reiss P, Samaras K; Working Group 1. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008;118:e20-8. [PMID: 18566314 DOI: 10.1161/CIRCULATIONAHA.107.189623] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
391 Volpe GE, Wanke CA, Imai CM, Heffernan KS, Kuvin JT, Mangili A. High-fat meals do not impair postprandial endothelial function in HIV-infected and uninfected men. AIDS Res Hum Retroviruses 2014;30:881-7. [PMID: 24892462 DOI: 10.1089/AID.2013.0272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
392 Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 2008;22 Suppl 3:S19-26. [PMID: 18845918 DOI: 10.1097/01.aids.0000327512.76126.6e] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
393 Martin A, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second-Line Study Team. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One 2013;8:e77138. [PMID: 24204757 DOI: 10.1371/journal.pone.0077138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
394 Rodriguez-Penney AT, Iudicello JE, Riggs PK, Doyle K, Ellis RJ, Letendre SL, Grant I, Woods SP; HIV Neurobehavioral Research Program HNRP Group. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS 2013;27:5-16. [PMID: 23305257 DOI: 10.1089/apc.2012.0329] [Cited by in Crossref: 204] [Cited by in F6Publishing: 199] [Article Influence: 22.7] [Reference Citation Analysis]
395 Singhania R, Kotler DP. Lipodystrophy in HIV patients: its challenges and management approaches. HIV AIDS (Auckl) 2011;3:135-43. [PMID: 22267946 DOI: 10.2147/HIV.S14562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
396 Pacek LR, Latkin C, Crum RM, Stuart EA, Knowlton AR. Interest in quitting and lifetime quit attempts among smokers living with HIV infection. Drug Alcohol Depend 2014;138:220-4. [PMID: 24602364 DOI: 10.1016/j.drugalcdep.2014.02.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
397 Pacek LR, Latkin C, Crum RM, Stuart EA, Knowlton AR. Current cigarette smoking among HIV-positive current and former drug users: associations with individual and social characteristics. AIDS Behav 2014;18:1368-77. [PMID: 24287787 DOI: 10.1007/s10461-013-0663-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
398 Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol 2019;16:745-59. [PMID: 31182833 DOI: 10.1038/s41569-019-0219-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
399 Bloch M, Jayewardene A, Vincent T, Linton N, Quan D, Gowers A. Effectiveness of a team intervention in reducing modifiable cardiovascular disease risk in HIV-infected subjects on antiretroviral therapy. J Int AIDS Soc 2014;17:19546. [PMID: 25394053 DOI: 10.7448/IAS.17.4.19546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
400 Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS 2017;31:2503-14. [PMID: 29112070 DOI: 10.1097/QAD.0000000000001675] [Cited by in Crossref: 44] [Cited by in F6Publishing: 19] [Article Influence: 8.8] [Reference Citation Analysis]
401 Caruso N, Chandra A, Kestler A. Development of Emergency Medicine in Botswana. African Journal of Emergency Medicine 2011;1:108-12. [DOI: 10.1016/j.afjem.2011.08.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
402 Nüesch R, Gayet-Ageron A, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Chautrakarn S, Ruxrungtham K, Hirschel B, Anaworanich J; STACCATO study group. The impact of combination antiretroviral therapy and its interruption on anxiety, stress, depression and quality of life in Thai patients. Open AIDS J 2009;3:38-45. [PMID: 19812705 DOI: 10.2174/1874613600903010038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
403 Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA; INSIGHT ESPRIT & SILCAAT study groups. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010;24:1877-86. [PMID: 20588170 DOI: 10.1097/QAD.0b013e32833b1b26] [Cited by in Crossref: 62] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
404 Kure A, Abebe A, Baza D, Paulos W. Overweight and obesity and associated factors among adult ART patients at Hawassa University Comprehensive Specialized Hospital, Southern Ethiopia. BMC Nutr 2022;8:62. [PMID: 35821078 DOI: 10.1186/s40795-022-00556-1] [Reference Citation Analysis]
405 Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M; Working Group 2. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118:e29-35. [PMID: 18566319 DOI: 10.1161/CIRCULATIONAHA.107.189624] [Cited by in Crossref: 233] [Cited by in F6Publishing: 133] [Article Influence: 16.6] [Reference Citation Analysis]
406 Falster K, Wand H, Donovan B, Anderson J, Nolan D, Watson K, Watson J, Law MG; Australian HIV Observational Database. Hospitalizations in a cohort of HIV patients in Australia, 1999-2007. AIDS 2010;24:1329-39. [PMID: 20559038 DOI: 10.1097/QAD.0b013e328339e245] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
407 Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS 2019;33:2387-91. [PMID: 31764103 DOI: 10.1097/QAD.0000000000002350] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
408 Beckman JA, Wood BR, Ard KL, Price CN, Solomon DA, Zuflacht JP, Milian J, Prenner JC, Sax PE. Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir. PLoS One 2017;12:e0181993. [PMID: 29023508 DOI: 10.1371/journal.pone.0181993] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
409 Gutiérrez F, Bernal E, Padilla S, Hernández I, Masiá M. Relationship between ankle-brachial index and carotid intima-media thickness in HIV-infected patients. AIDS 2008;22:1369-71. [PMID: 18580617 DOI: 10.1097/QAD.0b013e3282f7cb88] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
410 Akgün KM, Huang L, Morris A, Justice AC, Pisani M, Crothers K. Critical illness in HIV-infected patients in the era of combination antiretroviral therapy. Proc Am Thorac Soc 2011;8:301-7. [PMID: 21653532 DOI: 10.1513/pats.201009-060WR] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
411 Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, Xie Y, Martin JN, Ganz P, Deeks SG. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009;23:2021-7. [PMID: 19542863 DOI: 10.1097/QAD.0b013e32832e7140] [Cited by in Crossref: 117] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
412 Crum-Cianflone N, Krause D, Wessman D, Medina S, Stepenosky J, Brandt C, Boswell G. Fatty liver disease is associated with underlying cardiovascular disease in HIV-infected persons(*). HIV Med 2011;12:463-71. [PMID: 21251186 DOI: 10.1111/j.1468-1293.2010.00904.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
413 Jantarapakde J, Phanuphak N, Chaturawit C, Pengnonyang S, Mathajittiphan P, Takamtha P, Dungjun N, Pinyakorn S, Pima W, Prasithsirikul W, Phanuphak P. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. AIDS Patient Care STDS 2014;28:331-40. [PMID: 24914459 DOI: 10.1089/apc.2013.0294] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
414 Carnevale RC, de Godoi Rezende Costa Molino C, Visacri MB, Mazzola PG, Moriel P. Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study. Daru 2015;23:13. [PMID: 25889580 DOI: 10.1186/s40199-014-0074-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
415 Kowalska JD, Mocroft A, Blaxhult A, Colebunders R, van Lunzen J, Podlekareva D, Hansen AB, Machala L, Yust I, Benfield T; EuroSIDA Study Group. Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection. AIDS Res Hum Retroviruses 2007;23:1183-8. [PMID: 17961102 DOI: 10.1089/aid.2006.0292] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
416 Le CN, Hulgan T, Tseng CH, Milne GL, Lake JE. Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial. PLoS One 2017;12:e0170515. [PMID: 28118376 DOI: 10.1371/journal.pone.0170515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
417 Zanni MV, Schouten J, Grinspoon SK, Reiss P. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol. 2014;11:728-741. [PMID: 25331088 DOI: 10.1038/nrcardio.2014.167] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
418 Shang N, Xu H, Rindflesch TC, Cohen T. Identifying plausible adverse drug reactions using knowledge extracted from the literature. J Biomed Inform 2014;52:293-310. [PMID: 25046831 DOI: 10.1016/j.jbi.2014.07.011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
419 Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010;24:427-35. [PMID: 19910787 DOI: 10.1097/QAD.0b013e328334344e] [Cited by in Crossref: 63] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
420 Falster K, Choi JY, Donovan B, Duncombe C, Mulhall B, Sowden D, Zhou J, Law MG; Australian HIV Observational Database., TREAT Asia HIV Observational Database. AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS 2009;23:2323-36. [PMID: 19752715 DOI: 10.1097/QAD.0b013e328331910c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
421 Floridia M, Tamburrini E, Anzidei G, Tibaldi C, Guaraldi G, Guerra B, Meloni AM, Vimercati A, Molinari A, Pinnetti C, Dalzero S, Ravizza M; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Plasma lipid profile in pregnant women with HIV receiving nevirapine. AIDS Patient Care STDS 2009;23:147-52. [PMID: 19866532 DOI: 10.1089/apc.2008.0148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
422 Suy A, Martínez E, Coll O, Lonca M, Palacio M, de Lazzari E, Larrousse M, Milinkovic A, Hernández S, Blanco JL, Mallolas J, León A, Vanrell JA, Gatell JM. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006;20:59-66. [PMID: 16327320 DOI: 10.1097/01.aids.0000198090.70325.bd] [Cited by in Crossref: 130] [Cited by in F6Publishing: 123] [Article Influence: 8.1] [Reference Citation Analysis]
423 Rosenkranz SL, Yarasheski KE, Para MF, Reichman RC, Morse GD. Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. Metab Syndr Relat Disord 2007;5:163-73. [PMID: 18007962 DOI: 10.1089/met.2006.0034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
424 Ryom L, Mocroft A, Kirk O, Ross M, Reiss P, Fux CA, Morlat P, Moranne O, Smith C, El-Sadr W, Law M, Lundgren JD. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 2014;28:187-99. [PMID: 24361680 DOI: 10.1097/QAD.0000000000000042] [Cited by in Crossref: 49] [Cited by in F6Publishing: 29] [Article Influence: 6.1] [Reference Citation Analysis]
425 Kingsley LA, Deal J, Jacobson L, Budoff M, Witt M, Palella F, Calhoun B, Post WS. Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men. AIDS 2015;29:2427-34. [PMID: 26558542 DOI: 10.1097/QAD.0000000000000847] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
426 Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Semin Cancer Biol 2020;64:93-101. [PMID: 31330185 DOI: 10.1016/j.semcancer.2019.06.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
427 Cortazar F, Molnar MZ, Isakova T, Czira ME, Kovesdy CP, Roth D, Mucsi I, Wolf M. Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. Am J Transplant 2012;12:379-87. [PMID: 22054244 DOI: 10.1111/j.1600-6143.2011.03826.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
428 Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC, Battegay M, Bernasconi E, Böni J, Bucher H, Bürgisser P, Cattacin S, Cavassini M, Dubs R, Egger M, Elzi L, Erb P, Fantelli K, Fischer M, Flepp M, Fontana A, Francioli P, Furrer H, Gorgievski M, Günthard H, Hirschel B, Kaiser L, Kind C, Klimkait T, Lauper U, Ledergerber B, Opravil M, Paccaud F, Pantaleo G, Perrin L, Piffaretti J, Rudin C, Schmid P, Schüpbach J, Speck R, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S; the Swiss HIV Cohort Study. Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. Antiviral Therapy 2005;10:585-91. [DOI: 10.1177/135965350501000511] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
429 Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008;22:2143-53. [PMID: 18832878 DOI: 10.1097/QAD.0b013e3283112b77] [Cited by in Crossref: 170] [Cited by in F6Publishing: 92] [Article Influence: 12.1] [Reference Citation Analysis]
430 Iwuji CC, Churchill D, Bremner S, Perry N, To Y, Lambert D, Bruce C, Waters L, Orkin C, Geretti AM. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial. BMC Infect Dis 2020;20:524. [PMID: 32689975 DOI: 10.1186/s12879-020-05240-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
431 Coll B, Alonso-Villaverde C. Carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients. AIDS 2005;19:1936-7. [PMID: 16227814 DOI: 10.1097/01.aids.0000189564.87600.04] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
432 Anuurad E, Thomas-Geevarghese A, Devaraj S, Albu J, Minolfo R, El-Sadr WM, Lu G, Karmally W, Berglund L. Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy. Atherosclerosis 2008;198:192-7. [PMID: 17996872 DOI: 10.1016/j.atherosclerosis.2007.09.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
433 Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363. [PMID: 19361855 DOI: 10.1016/s0140-6736(09)60612-7] [Cited by in Crossref: 513] [Cited by in F6Publishing: 305] [Article Influence: 39.5] [Reference Citation Analysis]
434 Johns K, Saeedi R, Mancini GB, Bondy G. Ankle brachial index screening for occult vascular disease is not useful in HIV-positive patients. AIDS Res Hum Retroviruses 2010;26:955-9. [PMID: 20718628 DOI: 10.1089/aid.2009.0275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
435 Thiébaut R, Aurillac-Lavignolle V, Bonnet F, Ibrahim N, Cipriano C, Neau D, Dupon M, Dabis F, Mercié P; Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999-2004. AIDS 2005;19:729-31. [PMID: 15821400 DOI: 10.1097/01.aids.0000166097.46940.35] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
436 Jong E, Louw S, Meijers JC, de Kruif MD, ten Cate H, Büller HR, Mulder JW, van Gorp EC. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 2009;23:1001-7. [PMID: 19929230 DOI: 10.1089/apc.2009.0173] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
437 Beires MT, Silva-Pinto A, Santos AC, Madureira AJ, Pereira J, Carvalho D, Sarmento A, Freitas P. Visceral adipose tissue and carotid intima-media thickness in HIV-infected patients undergoing cART: a prospective cohort study. BMC Infect Dis 2018;18:32. [PMID: 29325542 DOI: 10.1186/s12879-017-2884-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
438 Bernal E, Masiá M, Padilla S, Gutiérrez F. High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDS 2008;22:569-75. [PMID: 18479224 DOI: 10.1089/apc.2007.0186] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
439 Buchacz K, Baker RK, Moorman AC, Richardson JT, Wood KC, Holmberg SD, Brooks JT; HIV Outpatient Study (HOPS) Investigators. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008;22:1345-54. [PMID: 18580614 DOI: 10.1097/QAD.0b013e328304b38b] [Cited by in Crossref: 103] [Cited by in F6Publishing: 68] [Article Influence: 7.4] [Reference Citation Analysis]
440 Masur H. Management of patients with HIV in the intensive care unit. Proc Am Thorac Soc 2006;3:96-102. [PMID: 16493156 DOI: 10.1513/pats.200511-122JH] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
441 Singh GJ, Jackson A, D'Avolio A, Else L, De Nicolò A, Bonora S, Di Perri G, Khoo S, Back D, Moyle G, Boffito M. No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. AIDS 2014;28:1993-5. [PMID: 25259708 DOI: 10.1097/QAD.0000000000000356] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
442 Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013;173:614-22. [PMID: 23459863 DOI: 10.1001/jamainternmed.2013.3728] [Cited by in Crossref: 738] [Cited by in F6Publishing: 732] [Article Influence: 82.0] [Reference Citation Analysis]
443 Jaggers JR, Dudgeon W, Blair SN, Sui X, Burgess S, Wilcox S, Hand GA. A home-based exercise intervention to increase physical activity among people living with HIV: study design of a randomized clinical trial. BMC Public Health 2013;13:502. [PMID: 23706094 DOI: 10.1186/1471-2458-13-502] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
444 Cao S, Woodrow KA. Nanotechnology approaches to eradicating HIV reservoirs. Eur J Pharm Biopharm 2019;138:48-63. [PMID: 29879528 DOI: 10.1016/j.ejpb.2018.06.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
445 Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am 2009;38:207-22. [PMID: 19217520 DOI: 10.1016/j.ecl.2008.11.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
446 Blodget E, Shen C, Aldrovandi G, Rollie A, Gupta SK, Stein JH, Dubé MP. Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS One 2012;7:e42624. [PMID: 22952600 DOI: 10.1371/journal.pone.0042624] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
447 Omar F, Dave JA, King JA, Levitt NS, Pillay TS. High Molecular Weight (HMW): total adiponectin ratio is low in hiv-infected women receiving protease inhibitors. BMC Clin Pathol 2014;14:46. [PMID: 25580091 DOI: 10.1186/1472-6890-14-46] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
448 Iwuala SO, Lesi OA, Fasanmade OA, Sabir AA, Olamoyegun MA, Okany CC. Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria. AIDS Res Treat 2015;2015:402638. [PMID: 25821597 DOI: 10.1155/2015/402638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
449 Wang SC, Kaur G, Schulman-Marcus J, Purga S, Mookherjee S, Miller C, Sidhu MS, Rosenson RS. Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV. Cardiovasc Drugs Ther 2020. [PMID: 32979175 DOI: 10.1007/s10557-020-07085-8] [Reference Citation Analysis]
450 Cotter BR. Endothelial dysfunction in HIV infection. Curr HIV/AIDS Rep 2006;3:126-31. [PMID: 16970839 DOI: 10.1007/BF02696656] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
451 Driscoll SD, Meininger GE, Lareau MT, Dolan SE, Killilea KM, Hadigan CM, Lloyd-Jones DM, Klibanski A, Frontera WR, Grinspoon SK. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004;18:465-73. [PMID: 15090799 DOI: 10.1097/00002030-200402200-00013] [Cited by in Crossref: 88] [Cited by in F6Publishing: 68] [Article Influence: 4.9] [Reference Citation Analysis]
452 Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc 2012;15:17426. [PMID: 23078769 DOI: 10.7448/IAS.15.2.17426] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
453 Hatleberg CI, Ryom L, El-Sadr W, Smith C, Weber R, Reiss P, Fontas E, Dabis F, Law M, Monforte Ad, De Wit S, Mocroft A, Phillips A, Lundgren JD, Sabin C; D:A:D Study Group. Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. AIDS 2016;30:1583-96. [PMID: 26950315 DOI: 10.1097/QAD.0000000000001076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
454 Yuan N, Scherzer R, Tanriverdi K, Martin J, Rahalkar S, Hsue P. MicroRNA biomarkers associated with type 1 myocardial infarction in HIV-positive individuals. AIDS 2019;33:2351-61. [PMID: 31764100 DOI: 10.1097/QAD.0000000000002368] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
455 Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008;22:2409-18. [PMID: 19005264 DOI: 10.1097/QAD.0b013e3283174636] [Cited by in Crossref: 191] [Cited by in F6Publishing: 122] [Article Influence: 13.6] [Reference Citation Analysis]
456 Zanetti HR, Roever L, Gonçalves A, Resende ES. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update. Curr Atheroscler Rep 2018;20:9. [PMID: 29423787 DOI: 10.1007/s11883-018-0708-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
457 McManus H, Petoumenos K, Brown K, Baker D, Russell D, Read T, Smith D, Wray L, Giles M, Hoy J, Carr A, Law MG; Australian HIV Observational Database. Loss to follow-up in the Australian HIV Observational Database. Antivir Ther 2015;20:731-41. [PMID: 25377928 DOI: 10.3851/IMP2916] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
458 Rosenson RS, Hubbard D, Monda KL, Reading SR, Chen L, Dluzniewski PJ, Burkholder GA, Muntner P, Colantonio LD. Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era. J Am Heart Assoc 2020;9:e013744. [PMID: 31880980 DOI: 10.1161/JAHA.119.013744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
459 Alanazi A, Ivanov A, Kumari N, Lin X, Wang S, Kovalskyy D, Nekhai S. Targeting Tat-TAR RNA Interaction for HIV-1 Inhibition. Viruses 2021;13:2004. [PMID: 34696435 DOI: 10.3390/v13102004] [Reference Citation Analysis]
460 Jiang B, Khandelwal AR, Rogers LK, Hebert VY, Kleinedler JJ, Zavecz JH, Shi W, Orr AW, Dugas TR. Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. Toxicol Sci 2010;117:524-36. [PMID: 20621964 DOI: 10.1093/toxsci/kfq213] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
461 Noumegni SR, Nansseu JR, Bigna JJ, Ama Moor VJ, Kembe Assah F, Dehayem MY, Kengne AP, Sobngwi E. Atherogenic index of plasma and 10-year risk of cardiovascular disease in adult Africans living with HIV infection: A cross-sectional study from Yaoundé, Cameroon. JRSM Cardiovasc Dis 2017;6:2048004017740478. [PMID: 29435266 DOI: 10.1177/2048004017740478] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
462 Baekken M, Os I, Sandvik L, Oektedalen O. Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant 2008;23:3130-7. [PMID: 18469311 DOI: 10.1093/ndt/gfn236] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
463 Kashyap S, Rabbani M, de Lima I, Kondrachuk O, Patel R, Shafiei MS, Mukker A, Rajakumar A, Gupta MK. HOPX Plays a Critical Role in Antiretroviral Drugs Induced Epigenetic Modification and Cardiac Hypertrophy. Cells 2021;10:3458. [PMID: 34943964 DOI: 10.3390/cells10123458] [Reference Citation Analysis]
464 Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373:795-807. [PMID: 26192873 DOI: 10.1056/nejmoa1506816] [Cited by in Crossref: 1583] [Cited by in F6Publishing: 992] [Article Influence: 226.1] [Reference Citation Analysis]
465 Lai S, Fishman EK, Gerstenblith G, Brinker J, Tai H, Chen S, Li J, Tong W, Detrick B, Lai H. Vitamin D deficiency is associated with coronary artery calcification in cardiovascularly asymptomatic African Americans with HIV infection. Vasc Health Risk Manag 2013;9:493-500. [PMID: 24009422 DOI: 10.2147/VHRM.S48388] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
466 Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, Jones L, Alston-Smith B, Rooney JF, Aberg JA. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010;24:1781-4. [PMID: 20495438 DOI: 10.1097/QAD.0b013e32833ad8b4] [Cited by in Crossref: 88] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
467 Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, Koethe JR, Arnett DK, Kabagambe EK. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis 2013;12:50. [PMID: 23575345 DOI: 10.1186/1476-511X-12-50] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
468 Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M; D:A:D Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med 2011;12:412-21. [PMID: 21251183 DOI: 10.1111/j.1468-1293.2010.00901.x] [Cited by in Crossref: 128] [Cited by in F6Publishing: 119] [Article Influence: 11.6] [Reference Citation Analysis]
469 So-Armah K, Freiberg MS. Cardiovascular disease risk in an aging HIV population: not just a question of biology. Curr Opin HIV AIDS 2014;9:346-54. [PMID: 24824885 DOI: 10.1097/COH.0000000000000065] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
470 Cade WT, Reeds DN, Overton ET, Herrero P, Waggoner AD, Davila-Roman VG, Lassa-Claxton S, Gropler RJ, Soto PF, Krauss MJ, Yarasheski KE, Peterson LR. Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis. Cardiovasc Diabetol 2011;10:111. [PMID: 22151886 DOI: 10.1186/1475-2840-10-111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
471 Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64:910-28. [PMID: 19767318 DOI: 10.1093/jac/dkp334] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
472 Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N. Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc 2011;14:4. [PMID: 21255462 DOI: 10.1186/1758-2652-14-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
473 Ho JE, Scherzer R, Hecht FM, Maka K, Selby V, Martin JN, Ganz P, Deeks SG, Hsue PY. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS 2012;26:1115-20. [PMID: 22382147 DOI: 10.1097/QAD.0b013e328352ce54] [Cited by in Crossref: 60] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
474 Rider OJ, Asaad M, Ntusi N, Wainwright E, Clutton G, Hancock G, Banerjee R, Pitcher A, Samaras K, Clarke K, Neubauer S, Dorrell L, Holloway CJ. HIV is an independent predictor of aortic stiffness. J Cardiovasc Magn Reson 2014;16:57. [PMID: 25187084 DOI: 10.1186/s12968-014-0057-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
475 Wong G, Trevillyan JM, Fatou B, Cinel M, Weir JM, Hoy JF, Meikle PJ. Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction. PLoS One 2014;9:e94810. [PMID: 24733512 DOI: 10.1371/journal.pone.0094810] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
476 Mauri Pont M, Borrallo Almansa RM, Almada Rivas G, Carbó Díez M, Solé Arnau R, García Restoy E. [Peripheral arterial disease and cardiovascular risk factors among patients infected with human immunodeficiency virus: a comparison between hospital out-patients and patients in a prison]. Clin Investig Arterioscler 2014;26:115-21. [PMID: 24461720 DOI: 10.1016/j.arteri.2013.12.002] [Reference Citation Analysis]
477 Soliman EZ, Prineas RJ, Roediger MP, Duprez DA, Boccara F, Boesecke C, Stephan C, Hodder S, Stein JH, Lundgren JD, Neaton JD. Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. J Electrocardiol 2011;44:779-85. [PMID: 21145066 DOI: 10.1016/j.jelectrocard.2010.10.027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
478 Cutrono SE, Lewis JE, Perry A, Signorile J, Tiozzo E, Jacobs KA. The Effect of a Community-Based Exercise Program on Inflammation, Metabolic Risk, and Fitness Levels Among Persons Living with HIV/AIDS. AIDS Behav 2016;20:1123-31. [PMID: 26607928 DOI: 10.1007/s10461-015-1245-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
479 Sekhar RV, Jahoor F, Pownall HJ, Ballantyne CM, Balasubramanyam A. Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. Curr Atheroscler Rep 2004;6:173-9. [PMID: 15068741 DOI: 10.1007/s11883-004-0029-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
480 Pereira MT, Ferreira L, Horta AA, de Carvalho AC. Exogenous Cushing's syndrome as a result of ritonavir–budesonide interaction – A case report. HIV & AIDS Review 2016;15:91-3. [DOI: 10.1016/j.hivar.2016.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
481 Aje TO, Miller M. Cardiovascular disease: A global problem extending into the developing world. World J Cardiol 2009; 1(1): 3-10 [PMID: 21160570 DOI: 10.4330/wjc.v1.i1.3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
482 Han WM, Law MG, Choi JY, Ditangco R, Kumarasamy N, Chaiwarith R, Ly PS, Khusuwan S, Merati TP, Do CD, Yunihastuti E, Azwa I, Lee MP, Pham TN, Chan YJ, Kiertiburanakul S, Ng OT, Tanuma J, Pujari S, Zhang F, Gani Y, Mave V, Ross J, Avihingsanon A; TREAT Asia HIV Observational Database of IeDEA Asia-Pacific. Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. HIV Med 2021. [PMID: 34816562 DOI: 10.1111/hiv.13211] [Reference Citation Analysis]
483 Polanka BM, Kundu S, So-Armah KA, Freiberg MS, Gupta SK, Bedimo RJ, Budoff MJ, Butt AA, Chang CH, Gottlieb SS, Marconi VC, Womack JA, Stewart JC. Insomnia as an Independent Predictor of Incident Cardiovascular Disease in HIV: Data From the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr 2019;81:110-7. [PMID: 30768487 DOI: 10.1097/QAI.0000000000001981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
484 Dawood FZ, Roediger MP, Grandits G, Miller D, Fisher M, Zhang ZM, Hodder S, Hoy JF, Lundgren JD, Neaton JD, Soliman EZ; INSIGHT SMART Study Group. Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. J Electrocardiol 2014;47:264-71. [PMID: 24406207 DOI: 10.1016/j.jelectrocard.2013.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
485 Lake JE, Seang S, Kelesidis T, Liao DH, Hodis HN, Stein JH, Currier JS. Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study. HIV Clin Trials 2015;16:197-206. [PMID: 26360501 DOI: 10.1179/1945577115Y.0000000006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
486 Coll B, Alonso-Villaverde C, Parra S, Montero M, Tous M, Joven J, Masana L. The stromal derived factor-1 mutated allele (SDF1-3'A) is associated with a lower incidence of atherosclerosis in HIV-infected patients. AIDS 2005;19:1877-83. [PMID: 16227796 DOI: 10.1097/01.aids.0000183516.22266.dd] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
487 Miller TL, Somarriba G, Orav EJ, Mendez AJ, Neri D, Schaefer N, Forster L, Goldberg R, Scott GB, Lipshultz SE. Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1. J Acquir Immune Defic Syndr 2010;55:182-8. [PMID: 20531209 DOI: 10.1097/QAI.0b013e3181e222c9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
488 Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 2007;81:11016-31. [PMID: 17686878 DOI: 10.1128/JVI.01340-07] [Cited by in Crossref: 88] [Cited by in F6Publishing: 68] [Article Influence: 5.9] [Reference Citation Analysis]
489 Hürlimann D, Chenevard R, Ruschitzka F, Flepp M, Enseleit F, Béchir M, Kobza R, Muntwyler J, Ledergerber B, Lüscher TF, Noll G, Weber R. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart 2006;92:110-2. [PMID: 15797933 DOI: 10.1136/hrt.2004.056523] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
490 Ranade K, Geese WJ, Noor M, Flint O, Tebas P, Mulligan K, Powderly W, Grinspoon SK, Dube MP. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 2008;22:1561-8. [PMID: 18670214 DOI: 10.1097/QAD.0b013e32830a9886] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
491 Todowede OO, Sartorius B, Magula N, Schutte AE. Association of predicted 10 years cardiovascular mortality risk with duration of HIV infection and antiretroviral therapy among HIV-infected individuals in Durban, South Africa. Diabetol Metab Syndr 2019;11:105. [PMID: 31890039 DOI: 10.1186/s13098-019-0502-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
492 Quiles N, Ortiz A. Prevalence of Cardiometabolic Risk Factors Among People Living with HIV in Southern Texas. AIDS Res Hum Retroviruses 2021;37:862-9. [PMID: 34139880 DOI: 10.1089/AID.2021.0019] [Reference Citation Analysis]
493 Miller TL, Orav EJ, Lipshultz SE, Arheart KL, Duggan C, Weinberg GA, Bechard L, Furuta L, Nicchitta J, Gorbach SL, Shevitz A. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr 2008;153:491-7. [PMID: 18538789 DOI: 10.1016/j.jpeds.2008.04.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
494 Desvarieux M, Boccara F, Meynard JL, Bastard JP, Mallat Z, Charbit B, Demmer RT, Haddour N, Fellahi S, Tedgui A, Cohen A, Capeau J, Boyd A, Girard PM. Infection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV-infected never-smokers independent of antiretroviral therapy. AIDS 2013;27:2603-14. [PMID: 24100713 DOI: 10.1097/QAD.0b013e3283634819] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
495 Lichtenstein KA. Antiretroviral treatment interruptions and risk of non-opportunistic diseases. Curr HIV/AIDS Rep 2009;6:77-82. [PMID: 19358778 DOI: 10.1007/s11904-009-0012-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
496 Tougouma JB, Yaméogo AA, Yaméogo NV, Hema A, Hien H, Kambiré Y, Poda A, Zoungrana J, Zabsonré P. [High incidence of asymptomatic myocardial ischemia in a population of HIV-infected patients in Bobo-Dioulasso, Burkina Faso]. Pan Afr Med J 2021;38:173. [PMID: 33995780 DOI: 10.11604/pamj.2021.38.173.9509] [Reference Citation Analysis]
497 Rasmussen LD, Omland LH, Pedersen C, Gerstoft J, Kronborg G, Jensen J, Obel N. Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study. BMC Infect Dis 2010;10:169. [PMID: 20546604 DOI: 10.1186/1471-2334-10-169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
498 Levitt NS, Steyn K, Dave J, Bradshaw D. Chronic noncommunicable diseases and HIV-AIDS on a collision course: relevance for health care delivery, particularly in low-resource settings--insights from South Africa. Am J Clin Nutr 2011;94:1690S-6S. [PMID: 22089433 DOI: 10.3945/ajcn.111.019075] [Cited by in Crossref: 105] [Cited by in F6Publishing: 111] [Article Influence: 9.5] [Reference Citation Analysis]
499 Munger AM, Chow DC, Playford MP, Parikh NI, Gangcuangco LM, Nakamoto BK, Kallianpur KJ, Ndhlovu LC, Shikuma CM, Mehta NN. Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens. AIDS Res Hum Retroviruses 2015;31:221-8. [PMID: 25416403 DOI: 10.1089/AID.2014.0239] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
500 Soliman EZ, Sharma S, Arastéh K, Wohl D, Achhra A, Tambussi G, O'Connor J, Stein JH, Duprez DA, Neaton JD, Phillips A; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015;16 Suppl 1:46-54. [PMID: 25711323 DOI: 10.1111/hiv.12233] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
501 Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS 2010;24:789-802. [PMID: 20224307 DOI: 10.1097/QAD.0b013e328337afdf] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
502 Taylor KA, Smyth E, Rauzi F, Cerrone M, Khawaja AA, Gazzard B, Nelson M, Boffito M, Emerson M. Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk. Br J Pharmacol 2019;176:879-89. [PMID: 30681136 DOI: 10.1111/bph.14589] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
503 Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther 2009;14:165-79. [PMID: 19430091 DOI: 10.1177/135965350901400203] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
504 Carr A, Amin J. Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS 2009;23:343-53; discussion 355-6. [PMID: 19114855 DOI: 10.1097/QAD.0b013e32831db232] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
505 Everson F, Genis A, Ogundipe T, De Boever P, Goswami N, Lochner A, Blackhurst D, Strijdom H. Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats. PLoS One 2018;13:e0208537. [PMID: 30517206 DOI: 10.1371/journal.pone.0208537] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
506 Honda M, Oka S. Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Int J Hematol 2006;84:18-22. [PMID: 16867897 DOI: 10.1532/IJH97.06102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
507 Sun K, Zhou S, Chen RY, Cohen MS, Zhang F. Recent key advances in human immunodeficiency virus medicine and implications for China. AIDS Res Ther 2010;7:12. [PMID: 20500898 DOI: 10.1186/1742-6405-7-12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
508 Grinsztejn B, Di Perri G, Towner W, Woodfall B, De Smedt G, Peeters M. A review of the safety and tolerability profile of the next-generation NNRTI etravirine. AIDS Res Hum Retroviruses 2010;26:725-33. [PMID: 20624073 DOI: 10.1089/aid.2009.0293] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
509 Fuchs SC, Alencastro PR, Ikeda ML, Barcellos NT, Wolff FH, Brandão AB, Ximenes RA, Miranda-Filho Dde B, Lacerda HR, de Albuquerque Mde F, Montarroyos UR, Nery MW, Turchi MD. Risk of coronary heart disease among HIV-infected patients: a multicenter study in Brazil. ScientificWorldJournal 2013;2013:163418. [PMID: 24223499 DOI: 10.1155/2013/163418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
510 Blázquez D, Ramos-Amador JT, Saínz T, Mellado MJ, García-Ascaso M, De José MI, Rojo P, Navarro ML, Muñoz-Fernández MÁ, Saavedra J, Roa MA, Jiménez S, Beceiro J, Prieto L, Hortelano MG, González-Tomé MI. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infect Dis 2015;15:119. [PMID: 25880777 DOI: 10.1186/s12879-015-0853-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
511 Hsieh E, Yin MT. Continued Interest and Controversy: Vitamin D in HIV. Curr HIV/AIDS Rep 2018;15:199-211. [PMID: 29713871 DOI: 10.1007/s11904-018-0401-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
512 Maisa A, Hearps AC, Angelovich TA, Pereira CF, Zhou J, Shi MD, Palmer CS, Muller WA, Crowe SM, Jaworowski A. Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration. AIDS 2015;29:1445-57. [PMID: 26244384 DOI: 10.1097/QAD.0000000000000739] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
513 Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dubé MP, Lipshultz SE, Hsue PY, Squires K, Schambelan M, Wilson PW, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008;118:198-210. [PMID: 18566320 DOI: 10.1161/CIRCULATIONAHA.107.189622] [Cited by in Crossref: 160] [Cited by in F6Publishing: 74] [Article Influence: 11.4] [Reference Citation Analysis]
514 Grubb JR, Moorman AC, Baker RK, Masur H. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 2006;20:1095-107. [PMID: 16691060 DOI: 10.1097/01.aids.0000226949.64600.f9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
515 Leach LL, Bassett SH, Smithdorf G, Andrews BS, Travill AL. A Systematic Review of the Effects of Exercise Interventions on Body Composition in HIV+ Adults. Open AIDS J 2015;9:66-79. [PMID: 26587075 DOI: 10.2174/1874613601509010066] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
516 Dubé MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, Roubenoff R, Shafer RW, Wininger DA, Meyer WA 3rd, Snyder SW, Mulligan K. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-18. [PMID: 16227788 DOI: 10.1097/01.aids.0000183629.20041.bb] [Cited by in Crossref: 156] [Cited by in F6Publishing: 134] [Article Influence: 9.2] [Reference Citation Analysis]
517 Hatleberg CI, Ryom L, Kamara D, De Wit S, Law M, Phillips A, Reiss P, D'Arminio Monforte A, Mocroft A, Pradier C, Kirk O, Kovari H, Bonnet F, El-Sadr W, Lundgren JD, Sabin C; D:A:D Study Group. Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. EClinicalMedicine 2019;13:91-100. [PMID: 31517266 DOI: 10.1016/j.eclinm.2019.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
518 Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A, Thorne C; European Paediatric HIV and Lipodystrophy Study Group in EuroCoord. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr 2012;59:314-24. [PMID: 22205436 DOI: 10.1097/QAI.0b013e31824330cb] [Cited by in Crossref: 44] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
519 Shahbaz S, Manicardi M, Guaraldi G, Raggi P. Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk? World J Cardiol 2015; 7(10): 633-644 [PMID: 26516417 DOI: 10.4330/wjc.v7.i10.633] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
520 Hasse B, Tarr PE, Marques-Vidal P, Waeber G, Preisig M, Mooser V, Valeri F, Djalali S, Andri R, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Battegay M, Weber R, Senn O, Vollenweider P, Ledergerber B, Aubert V, Barth J, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schöni-Affolter F, Schmid P, Schultze D, Schüpbach J, Speck R, Staehelin C, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S, Jean-Michel A, Murielle B, Jean Michel G, Christoph H, Thomas L, Pedro MV, Vincent M, Fred P, Martin P, Peter V, Roland VK, Aidacic V, Gerard W, Jürg B, Markus B, Heinz B, Martin B, Hans-Ulrich B, Ivo B, Reto C, Isabelle C, Corinne C, Sima D, Peter D, Simone E, Andrea F, Markus F, Claudius F, Jakob F, Ali GM, Matthias G, Denis H, Marcel H, Walter H, Simon H, Felix H, Paul H, Eva K, Vladimir K, Daniel K, Stephan K, Beat K, Benedict K, Heidi K, Vesna L, Giovanni L, Werner LH, Phillippe L, Severin L, Christoph M, Jürgen M, Damian M, Werner M, Titus M, Valentina N, Jakob R, Thomas R, Hana S, Frank S, Georg S, Oliver S, Pietro S, Jacques S, Alfred S, Alois S, Claudia S, Othmar S, Phuoc TT, Marco V, Alessandro V, René VA, Hans W, Fritz W, Johanna WS, Joseph W, Marco Z; CoLaus Cohort, FIRE and the Swiss HIV Cohort Study. Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. Open Forum Infect Dis 2015;2:ofv108. [PMID: 26284258 DOI: 10.1093/ofid/ofv108] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
521 Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV/AIDS Rep 2020;17:138-50. [PMID: 32072466 DOI: 10.1007/s11904-020-00483-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
522 Miller TI, Borkowsky W, DiMeglio LA, Dooley L, Geffner ME, Hazra R, McFarland EJ, Mendez AJ, Patel K, Siberry GK, Van Dyke RB, Worrell CJ, Jacobson DL, Shearer W, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Patton D, Burchett S, Karthas N, Kammerer B, Yogev R, Malee K, Hunter S, Cagwin E, Wiznia A, Burey M, Nozyce M, Chen J, Gobs E, Grant M, Knapp K, Allison K, Garvie P, Acevedo-Flores M, Rios H, Olivera V, Silio M, Borne C, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Barr E, Chambers C, Watson D, Messenger N, Belanger R, Dieudonne A, Bettica L, Adubato S, Scott G, Himic L, Willen E; Pediatric HIV/AIDS Cohort Study (PHACS). Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med 2012;13:264-75. [PMID: 22136114 DOI: 10.1111/j.1468-1293.2011.00970.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
523 Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog 2015;11:e1005063. [PMID: 26225566 DOI: 10.1371/journal.ppat.1005063] [Cited by in Crossref: 178] [Cited by in F6Publishing: 169] [Article Influence: 25.4] [Reference Citation Analysis]
524 Ghura S, Gross R, Jordan-Sciutto K, Dubroff J, Schnoll R, Collman RG, Ashare RL. Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy. J Neuroimmune Pharmacol 2020;15:694-714. [PMID: 31834620 DOI: 10.1007/s11481-019-09897-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
525 Ledgerwood DM, Yskes R. Smoking Cessation for People Living With HIV/AIDS: A Literature Review and Synthesis. Nicotine Tob Res 2016;18:2177-84. [PMID: 27245237 DOI: 10.1093/ntr/ntw126] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
526 LaBounty TM, Hardy WD, Fan Z, Yumul R, Li D, Dharmakumar R, Conte AH. Carotid artery thickness is associated with chronic use of highly active antiretroviral therapy in patients infected with human immunodeficiency virus: A 3.0 Tesla magnetic resonance imaging study. HIV Med 2016;17:516-23. [PMID: 26634886 DOI: 10.1111/hiv.12351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
527 Rasmussen LD, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Obel N. Mortality after myocardial infarction in HIV-infected patients who have initiated HAART. AIDS 2007;21:873-5. [PMID: 17415045 DOI: 10.1097/QAD.0b013e3280b07dc6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
528 Osoti A, Temu TM, Kirui N, Ngetich EK, Kamano JH, Page S, Farquhar C, Bloomfield GS. Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya. AIDS Patient Care STDS 2018;32:215-22. [PMID: 29851503 DOI: 10.1089/apc.2018.0052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
529 Skamra C, Ramsey-Goldman R. Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol 2010;5:75-100. [PMID: 20305727 DOI: 10.2217/ijr.09.73] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
530 Gutierrez J, Rosoklija G, Murray J, Chon C, Elkind MS, Goldman J, Honig LS, Dwork AJ, Morgello S, Marshall RS. A quantitative perspective to the study of brain arterial remodeling of donors with and without HIV in the Brain Arterial Remodeling Study (BARS). Front Physiol 2014;5:56. [PMID: 24600402 DOI: 10.3389/fphys.2014.00056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
531 Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JD; EuroSIDA Study Group. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005;21:527-36. [PMID: 15989457 DOI: 10.1089/aid.2005.21.527] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
532 Egaña-Gorroño L, Martínez E, Cormand B, Escribà T, Gatell J, Arnedo M. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy. AIDS 2013;27:529-38. [PMID: 23262498 DOI: 10.1097/QAD.0b013e32835d0da1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
533 Yan C, Li R, Guo X, Yu H, Li W, Li W, Ren M, Yang M, Li H. Cardiac Involvement in Human Immunodeficiency Virus Infected Patients: An Observational Cardiac Magnetic Resonance Study. Front Cardiovasc Med 2021;8:756162. [PMID: 34869667 DOI: 10.3389/fcvm.2021.756162] [Reference Citation Analysis]
534 Schambelan M, Wilson PW, Yarasheski KE, Cade WT, Dávila-Román VG, D'Agostino RB Sr, Helmy TA, Law M, Mondy KE, Nachman S, Peterson LR, Worm SW; Working Group 5. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008;118:e48-53. [PMID: 18566316 DOI: 10.1161/CIRCULATIONAHA.107.189627] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
535 Eyawo O, Brockman G, Goldsmith CH, Hull MW, Lear SA, Bennett M, Guillemi S, Franco-Villalobos C, Adam A, Mills EJ, Montaner JSG, Hogg RS. Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis. BMJ Open 2019;9:e025874. [PMID: 31551371 DOI: 10.1136/bmjopen-2018-025874] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
536 Feeney ER, Mallon PW. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J 2011;5:49-63. [PMID: 21643501 DOI: 10.2174/1874192401105010049] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 7.6] [Reference Citation Analysis]
537 Feeney E, Muldoon E, Powderly WG. Management of antiretroviral drug toxicity. Curr Opin HIV AIDS 2006;1:430-6. [PMID: 19372843 DOI: 10.1097/01.COH.0000239856.45485.db] [Reference Citation Analysis]
538 Dorey-Stein Z, Amorosa VK, Kostman JR, Lo Re V 3rd, Shannon RP. Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy. J Cardiometab Syndr 2008;3:111-4. [PMID: 18453812 DOI: 10.1111/j.1559-4572.2008.07552.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
539 Kaplan-Lewis E, Aberg JA, Lee M. Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy. Curr HIV/AIDS Rep 2016;13:297-308. [PMID: 27562769 DOI: 10.1007/s11904-016-0331-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
540 Pillay B, Ramdial PK, Naidoo DP. HIV-associated large-vessel vasculopathy: a review of the current and emerging clinicopathological spectrum in vascular surgical practice. Cardiovasc J Afr 2015;26:70-81. [PMID: 25940120 DOI: 10.5830/CVJA-2015-017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
541 Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 2011;214:468-73. [PMID: 21130995 DOI: 10.1016/j.atherosclerosis.2010.11.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
542 Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 2010;15:1077-86. [PMID: 21149914 DOI: 10.3851/IMP1681] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
543 Teasdale CA, Hernandez C, Zerbe A, Chege D, Hawken M, El-Sadr WM. Changes in D-dimer after initiation of antiretroviral therapy in adults living with HIV in Kenya. BMC Infect Dis 2020;20:508. [PMID: 32664854 DOI: 10.1186/s12879-020-05213-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
544 Cespedes MS, Aberg JA. Cardiovascular and Endothelial Disease in HIV Infection. Curr Infect Dis Rep 2005;7:309-15. [PMID: 15963333 DOI: 10.1007/s11908-005-0064-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
545 Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. PLoS One 2012;7:e41673. [PMID: 22911841 DOI: 10.1371/journal.pone.0041673] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
546 Navarrete-Muñoz MA, Llorens C, Benito JM, Rallón N. Extracellular Vesicles as a New Promising Therapy in HIV Infection. Front Immunol 2021;12:811471. [PMID: 35058938 DOI: 10.3389/fimmu.2021.811471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
547 Egaña-Gorroño L, Martínez E, Escribà T, Calvo M, Gatell JM, Arnedo M. Association study of lipoprotein(a) genetic markers, traditional risk factors, and coronary heart disease in HIV-1-infected patients. Front Immunol 2012;3:367. [PMID: 23230442 DOI: 10.3389/fimmu.2012.00367] [Reference Citation Analysis]
548 Foley J, Ettenhofer M, Wright MJ, Siddiqi I, Choi M, Thames AD, Mason K, Castellon S, Hinkin CH. Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol 2010;24:265-85. [PMID: 20162495 DOI: 10.1080/13854040903482830] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
549 Pinto DSM, da Silva MJLV. Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection. Curr Cardiol Rev 2018;14:25-41. [PMID: 29189172 DOI: 10.2174/1573403X13666171129170046] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
550 Wang X, Liao D, Lin PH, Yao Q, Chen C. Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells. Lab Invest 2009;89:1355-63. [PMID: 19770838 DOI: 10.1038/labinvest.2009.85] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
551 Singh MV, Kotla S, Le NT, Ae Ko K, Heo KS, Wang Y, Fujii Y, Thi Vu H, McBeath E, Thomas TN, Jin Gi Y, Tao Y, Medina JL, Taunton J, Carson N, Dogra V, Doyley MM, Tyrell A, Lu W, Qiu X, Stirpe NE, Gates KJ, Hurley C, Fujiwara K, Maggirwar SB, Schifitto G, Abe JI. Senescent Phenotype Induced by p90RSK-NRF2 Signaling Sensitizes Monocytes and Macrophages to Oxidative Stress in HIV-Positive Individuals. Circulation 2019;139:1199-216. [PMID: 30586719 DOI: 10.1161/CIRCULATIONAHA.118.036232] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
552 Nasta P, Gatti F, Puoti M, Cologni G, Bergamaschi V, Borghi F, Matti A, Ricci A, Carosi G. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 2008;22:857-61. [PMID: 18427204 DOI: 10.1097/QAD.0b013e3282fbd1c4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 2.1] [Reference Citation Analysis]
553 Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol 2005;79:8454-69. [PMID: 15956589 DOI: 10.1128/JVI.79.13.8454-8469.2005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
554 Cade WT, Reeds DN, Lassa-Claxton S, Davila-Roman VG, Waggoner AD, Powderly WG, Yarasheski KE. Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease? HIV Med 2008;9:96-100. [PMID: 18093131 DOI: 10.1111/j.1468-1293.2007.00524.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
555 Gharib AM, Hadigan C. Imaging to End Points: Cardiovascular Disease Risk Assessment in HIV. Circ Cardiovasc Imaging 2017;10:e007120. [PMID: 29021266 DOI: 10.1161/CIRCIMAGING.117.007120] [Reference Citation Analysis]
556 Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven DE, Horsburgh CR Jr. Endothelial function in HIV-infected persons. Clin Infect Dis 2006;42:1325-32. [PMID: 16586393 DOI: 10.1086/503261] [Cited by in Crossref: 129] [Cited by in F6Publishing: 134] [Article Influence: 8.1] [Reference Citation Analysis]
557 Vernon LT, Babineau DC, Demko CA, Lederman MM, Wang X, Toossi Z, Weinberg A, Rodriguez B. A prospective cohort study of periodontal disease measures and cardiovascular disease markers in HIV-infected adults. AIDS Res Hum Retroviruses 2011;27:1157-66. [PMID: 21443451 DOI: 10.1089/AID.2010.0320] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
558 Baranoski AS, Harris A, Michaels D, Miciek R, Storer T, Sebastiani P, Montano M. Relationship between poor physical function, inflammatory markers, and comorbidities in HIV-infected women on antiretroviral therapy. J Womens Health (Larchmt) 2014;23:69-76. [PMID: 24219874 DOI: 10.1089/jwh.2013.4367] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
559 Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JD; EuroSIDA Study Group. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005;21:743-52. [PMID: 16218797 DOI: 10.1089/aid.2005.21.743] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
560 Gwee A, Cranswick N. Anti-infective use in children and pregnancy: current deficiencies and future challenges. Br J Clin Pharmacol 2015;79:216-21. [PMID: 24588467 DOI: 10.1111/bcp.12363] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
561 von Hentig N. Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy. HIV AIDS (Auckl) 2016;8:1-16. [PMID: 26730211 DOI: 10.2147/HIV.S70836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
562 Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D’Arminio Monforte A, Friis-Møller N. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426. [PMID: 18387667 DOI: 10.1016/s0140-6736(08)60423-7] [Cited by in Crossref: 585] [Cited by in F6Publishing: 230] [Article Influence: 41.8] [Reference Citation Analysis]
563 Helsley RN, Sui Y, Ai N, Park SH, Welsh WJ, Zhou C. Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice. Mol Pharmacol 2013;83:1190-9. [PMID: 23519392 DOI: 10.1124/mol.113.085753] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
564 Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S; INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21:2445-53. [PMID: 18025881 DOI: 10.1097/QAD.0b013e3282efad32] [Cited by in Crossref: 138] [Cited by in F6Publishing: 78] [Article Influence: 9.2] [Reference Citation Analysis]
565 Baker JV, Sabin CA. Does antiretroviral therapy started at high CD4 cell counts reduce an individual HIV-positive patient's disease risk? Curr Opin HIV AIDS 2014;9:1-3. [PMID: 24225383 DOI: 10.1097/COH.0000000000000026] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
566 Boettiger DC, Sabin CA, Grulich A, Ryom L, Bonnet F, Reiss P, Monforte Ad, Kirk O, Phillips A, Bower M, Fätkenheuer G, Lundgren JD, Law M; Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group. Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? AIDS 2016;30:1629-37. [PMID: 26854812 DOI: 10.1097/QAD.0000000000001053] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
567 Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis 2012;59:628-35. [PMID: 22206742 DOI: 10.1053/j.ajkd.2011.10.050] [Cited by in Crossref: 92] [Cited by in F6Publishing: 92] [Article Influence: 8.4] [Reference Citation Analysis]
568 Lekakis J, Ikonomidis I, Palios J, Tsiodras S, Karatzis E, Poulakou G, Rallidis L, Antoniadou A, Panagopoulos P, Papadopoulos A, Triantafyllidi H, Giamarellou H, Kremastinos DT. Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus. Am J Hypertens 2009;22:828-34. [PMID: 19556973 DOI: 10.1038/ajh.2009.90] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
569 Lai S, Fishman EK, Lai H, Moore R, Cofrancesco J Jr, Pannu H, Tong W, Du J, Barlett J. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Clin Infect Dis 2008;46:600-10. [PMID: 19641630 DOI: 10.1086/526782] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
570 Chau KH, Scherzer R, Grunfeld C, Hsue PY, Shlipak MG. CHA2DS2-VASc Score, Warfarin Use, and Risk for Thromboembolic Events Among HIV-Infected Persons With Atrial Fibrillation. J Acquir Immune Defic Syndr 2017;76:90-7. [PMID: 28797024 DOI: 10.1097/QAI.0000000000001470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
571 Glass TR, De Geest S, Hirschel B, Battegay M, Furrer H, Cavassini M, Vernazza PL, Bernasconi E, Rickenbach M, Weber R, Bucher HC; the Swiss HIV Cohort Study. Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients. Antiviral Therapy 2008;13:77-86. [DOI: 10.1177/135965350801300108] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]